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FOREWORD 
Dr. Starzl's monograph is so extraordinary we have asked two 
uthet' eminent surgical students of the portal circulation to com-
ment. Dr. Dean Warren's appreciation precedes the monograph 
and Dr. William V, McDermott's critique follows it. 
MAIm 1\1. ({AVln'lI, rvl.LJ. 
E D1TOIl-IN-C III EF 
COMMENT 
This monograph of Eck's fistula by Starzl is the most author-
itative publication since that by Pavlov and his associates in 
1893. Pavlov pointed out the near-total lack of scientific data 
available frolll Eck's study, but commented that the operation 
would be important because it could open doors for the clarifi-
cation of important problems in the pathology, physiology, and 
pharmacology of the liver. 
No one has grasped this opportunity with the brilliance and 
dedication of Starzl, and in this arena he has no peers, I know 
of no other source from which this outstanding scientific and 
clinical correlation could have come. 
W. DEAN W;\HHEN, 1\1.D. 
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SELF-ASSESSMENT QUESTIONS 
1. The most important hepatotrophic hormone or substance is: 
a. Phenylalanine. 
b. Glucagon. 
c. Epinephrine. 
d. Insulin. 
2. Side-to-side portacaval shunts reduce encephalopathy by 
maintaining partial portal perfusion of the liver. True or 
false? 
3. Dean Warren is Dean of the following medical school: 
a. Washington University. 
b. Johns Hopkins. 
c. Emory. 
d. None of the above. 
4. The unique feature of the Warren shunt is its: 
a. High flow. 
b. Unusual efficiency in decompressing esophageal varices. 
c. Partial maintenance of hepatopetal portal flow. 
5. In animals or humans with normal livers, completely di-
verting portacaval shunt causes: 
a. Hepatocyte atrophy. 
b. Deglycogenation. 
c. Reduction and disruption of rough endoplasmic reticu-
lum. 
d. Intracellular fat deposition. 
6. The risks of encepalopathy after portacaval shunt are 
greater the more normal the preexisting hepatic function. 
True or false? 
7. The metabolic effects of completely diverting portacaval 
shunt have been used to treat at least three inborn errors of 
metabolism. True or false? 
8. Both completely diverting and selective portal-systemic 
shunts greatly improve the life survival curves of patients 
with esophageal varices. True or false? 
9. Complete portal diversion causes subtle and clinically insig-
nificant changes in a few kinds of hepatic function. True or 
false? 
10. The liver has important and easily demonstrable immuno-
logic functions. True or false? 
Answers are found at the end of the article. 
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is a Professor of Surgery at the University 
of Pittsburgh School of Medicine. His clin-
ical practice is at the Presbyterian Univer-
sity Hospital, The Children's Hospital of 
Pittsburgh, and the Oakland Veterans Ad-
ministration Hospital. His interest in the 
specific effects of portal venous blood dates 
back to 1956. The way in which research 
in this field has interrelated with liver 
transplantation, another of his interests, 
has been described in this monograph. 
Much of the progress that was made in un-
derstanding "hepatotrophic" physiology 
was made possible by Dr.; Starzl's long-
standing collaborations with the two Eu-
ropean co-authors of this article. 
-is Chairman of the Department of Pathol-
ogy, The St. Mary's Hospital and Medical 
School, London. In September, 1963, Ken 
Porter and Torn Starzl (then at The Uni-
versity of Colorado) met at a meeting 
about renal transplantation, held at the 
National Science Foundation in Washing-
ton, D.C. The results being obtained with 
this procedure in Colorado were so striking 
that Dr. Porter returned to Denver with 
Dr. Starzl to review what was going on 
there. From that visit came a collaboration 
that has lasted for more than two decades. 
Dr. Porter's chapters in Dr. Starzl's books 
on renal (964) and hepatic (1969) trans-
plantation were monographs in their own 
right. Dr. Porter's talents soon turned to 
an assessment in various experimental 
models of the effect upon liver morphology 
of portal venous as opposed to systemic 
blood. The histopathologic changes became 
the most important end points in many of 
the complex experiments that were used to 
examine the hepatotrophic hypothesis. As 
befits an Englishman, Dr. Porter's princi-
pal side interest is gardening. 
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is Professor of Biological Chemistry and 
Chairman of the Department of Gastroen-
tcrology at the University of Bari, Italy. 
His principal work in the field of portal 
physiology began in 1971 during a fellow-
ship at the University of Colorado. By us-
ing biochemical techniques which identi-
fied the metabolic footprints of hormone 
actions, he added a new dimension to re-
search on the specificity of portal venous 
blood. The way in which Dr. Francavilla's 
biochemical studies supported and ex-
tended the histopathologic observations of 
Dr. Porter was a classic demonstration of 
the power of interdisciplinary research. Dr. 
Francavilla's work in this field has contin-
ued to the present time and is currently 
concerned with the biochemical events and 
control of hepatic regeneration. Dr. Fran-
cavilla's hobbies include soccer and the 
production of Puglia (rcginna I Baril wines. 
TilE DUAL BLOOD SUPPLY of the liver has been known for 
several centuries. However, the physiologic implications of this 
anatomical arrangement have become intelligible only in recent 
years. The fact that an artery passed to the liver was never con-
fusing, since there was no reason to suspect that it carried blood 
different from that pumped through other organs. 
In contrast, the portal vein was suspect. Because the blood in 
this vessel was returning from the intestine and other splanch-
nic organs, it could possess nutrients or other constituents from 
the non hepatic splanchnic viscera to which the liver would be 
exposed in high concentration on first pass. The possibility that 
such portal substances could be important to liver health be-
came known as the hepatotrophic hypothesis; confirmation of 
this hypothesis has been one of the most important recent de-
velopments in hepatic physiology. I 
The hepatotrophic concept has direct relevance to many clini-
cal problems, including those of liver transplantation and he-
patic regeneration. I, 2 However, our main concern in this mono-
graph is to explore how knowledge of hepatotrophic physiology 
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should influence decisions about the appropriateness, timing, 
and type of portacaval shunt in patients with portal hyperten-
sion and esophageal varices, or in the small number of patients 
w,hose. inborn errors of metabolism can be ameliorated by portal 
diverSIOn. 
THE PORTACAVAL SHUNT (ECK'S FISTULA): A CENTURY 
OF CONTROVERSY 
The understanding of Eck's fistula"'has gone through sevel'al 
stages. In this discussion, the beginnings of each stage will be 
described in order of occurrence. Often, however, significant de-
tails continued to accrue for years or decades about each funda-
mental step. Consequently, the remarks in the following sec-
tions refer to studies widely separated in time, in some instances 
as much as 100 years apart, 
ECK VERSUS PAVLOV 
Two remarkable articles on portal physiology were published 
in the 19th century, Both authors were Russian. Their similar-
ity ended there. 
Nicholas Eck was a 29-year-old military surgeon without 
training in laboratory investigation whose unique contribution 
to the medical literature was an article scarcely more than 1 
page long.:! In it, he cited the widespread belief that a liver de-
prived of its portal blood flow could not sustain life. He stated 
that he had overturned this erroneous opinion by constructing 
completely diverting portacaval anastomoses (later known as 
Eck's fistula) in eight dogs. Seven animals died during 01' shortly 
after the operation, The eighth recovered fully and was observed 
for 211:.! months before it escaped from the laboratory, never to be 
found. 
Eck envisioned the clinical use of his operation and. gave an 
explicit although brief account of this technique. His purpose he 
described as follows: 
I am conducting these experiments with the purpose of clarifying some 
physiologic problems as well as to determine if it would be possible to 
treat some cases of mechanical ascites by means of forming such a fis-
tula. I consider the main reason to doubt that such an operation can be 
carried out on human beings has been removed because it has been 
established that the blood of the portal vein, without any danger to the 
body, could be diverted directly into the general circulation and this by 
means of a perfectly safe operation. 
His optimism may have been excessive in view of the perioper-
ative mortality of 88tK. 
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Eck concluded his article with the comment, "I had to post-
pone further experiments because I was called to join the active 
army." Although his work in surgical physiology had ended, im-
mortality for Eck was assured. Warren4 has brought together 
the discoverable fragments of information about the subsequent 
career of this enigmatic surgeon. 
The second article, published in 1893 by Hahn, Massen, 
Nencki, and Pawlow,5 was one of the most incisive and original 
contributions ever made in the field of hepatology. Pawlow (Pav-
lov), the senior author, was 44 years old and just becoming an 
international figure as the result of research on behavioral psy-
chology and gastrointestinal physiology. His investigations were 
prototypic applications of the scientific method. He and his as-
sociates examined Eck's fistula in about 20 dogs. They described 
(complete with artist's illustrations) the primitive vascular an-
astomosis originally employed by Eck and in common use by the 
1890s. The portal vein (or superior mesenteric vein) and the in-
Fig 1.-The primitive technique 01 side-to-side portacaval anastomosis used by 
Eck3 and by Pavlov's group. Note that the connection between the two vessels was 
made by cutting or avulsing the adjacent walls inside a row of approximating simple 
sutures. The illustration is a photograph of the original drawing by Hahn el al.5 
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ferior vena cava were approximated with an oval row' of inter-
rupted sutures, inside of which a suture loop was inserted to 
permit the adjacent vessel walls to be avulsed or cut with a spe-
cially designed scissors (Fig 1). , : 
The size of the resulting aperture was unpredictable, and con-
sistent results by other investigators were not achieved until 
many years later, when the fine anastomotic techniques intro-
duced by Carrel and Guthrie6 found their way into surgical lab-
oratories (Fig 2). The side-to-side anastomosis of Eck's fistula 
was made completely diverting by tying ofT the portal vein su-
periorly (see Fig 2). _ .. . ... 
The benign nature of Eck's fistula was not confirmed by the 
Pavlov team. Animals with a good anastomosis had weight and 
hair loss. On a meat diet, they developed a neurologic disorder 
of ataxia and convulsions that presaged death. The syndrome 
was hepatic encephalopathy but was termed "meat intoxica-
tion," since it could be precipitated or aggravated by a meat diet. 
The main autopsy findings in Pavlov's animals after construc-
tion of Eck's fistula were atrophy and fatty infiltration of the 
liver.* Pavlov noted that these complex physiologic and morpho-
logical events did not occur or were minimized after shunt 
thrombosis or stenosis, or after revascularization by splanchnic 
collaterals of the tied-ofT portal vein above the site of the porta-
caval anastomosis. Such observations were still being made in 
more complicated and perhaps less convincing experiments more 
than 60 years later.B. 9 ' 
Three quarters of a century passed before it was realized that 
the atrophy caused by Eck's fistula occurred with astonishing 
rapidity, being 90% complete within 3-4 dayslll, 11 In addition 
the use of electron microscopy in recent years has made it pos~ 
sible to develop a clear picture of the organelle changes caused 
by PC!rtacaval shunt in the hepatocytes of previously normal 
rats 12--15 dogs 10.11. .16.17 subh 't 17 111 'd h 
" uman prIma es,' an u-
mans. 19. 20 
In all of these species the most striking and specific ultra-
structural changes were depletion and disruption of the rough 
endoplasmic reticulum (REm and reduction in the membrane-
bound polyribosomes (Fig 3).10, II, 16-18,20 Other features were 
fatty infiltration of the liver cells, a diminution in the number 
of glycogen granules, and deterioration of the appearance of the 
'Some of the earliest, if not the first, detailed illustrations of the histopath-
ology of the dog liver after Eck's fistula were published in the Bulletin of the 
Johns H?pk!ns Hospital in 1909 by George H. Whipple and J.A. Sperry.' Their 
main objectIve was to study chloroform intoxication, and the dogs with Eck's 
fistula (two in numberl were part of a control group. Whipple, who became a 
Nobel Laureate for work in the treatment of pernicious anemia, was the found-
ing dean of the University of Rochester School of Medicine. He died on ,Jan. 21, 
1976, at age 97. 
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Fig 2.-Completely diverting portacaval shunt (Eck's fistula). A side-to-side anas-
tomosis is constructed between the portal (or superior mesenteric) vein (P.v) and 
the anterolateral surface of the inferior vena cava (I. v.c). The shunt is made com-
pletely diverting by tying oil the portal vein in the hilum of the liver. (From Starzl et 
al. 7 Reproduced by permission.) 
mitochondria. In rats, Oudea and Bismuth 1:1 noted an increase 
in smooth endoplasmic reticulum (SER), but this was not prom-
inent in dogs, baboons, or humans. 
Another feature of the Eck fistula liver which escaped notice 
for a long time was a marked increase in hepatocyte renewalA 
which has been described in rats,14 dogs,lO· II and baboons. 17. I 
Aller portacaval shunt, the mitotic index and/or the rate of thy-
midine incorporation as measured by autoradiography rose 
within a few days to a new and stable level three or four times 
higher than the preoperative resting level. The stimulus for the 
low-grade hyperplasia is unknown. It may represent a response 
to an increased hepatocyte death rate. Since hepatocyte hyper-
plasia and hypertrophy are parallel in most situations of liver 
regeneration, the combination of atrophy and hyperplasia after 
Eck's fistula is a special situation that has generated much dis-
cussion. II. 14 
Rous VEHSUS MANN 
Peyton Rous and L.D. Larimore21 were intrigued by the pos-
sibilities that portal venous blood might contain hepatotrophic 
factors and that the extrahepatic diversion of these factors by 
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Fig 3.-Human liver biopsy appearances before (A) and after (B and C) porta-
caval shunt lor lamilial hypercholesterolemia. Rough endoplasmic reticulum (r) and 
glycogen are abundant in the preoperalive biopsy specimen. The hepatocyte is nor-
mal. Six months after portacaval anastomosis (B, C), there are major changes. 
Note that only isolated profiles 01 rough endoplasmic reticulum remain. Glycogen Is 
absent, and there are numerous lat droplets (electron micrographs; A, x 3015: B, 
x 5575; C, "25.100). (From Starzl et al. 20 Reproduced by permission.) 
portacaval shunt could be responsible for the hepatic atrophy 
and the poor health of animals with Eck's fistula. In 1924 they 
wrote, "Is the liver atrophy functional? If so, its completeness 
would indicate that that liver has no essential activity ... none 
on which its maintenance depends ... that is not intimately 
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connected with substances derived from organs drained by the 
portal system." Unfortunately, their experimental models did 
not permit decisive experiments that might have supported 
these suspicions. Rous was lost to the field of hepatology when 
he turned his attention to oncology. 
In contrast, F.C. Mann, of the Mayo Clinic, maintained an in-
terest in hepatic and gastrointestinal physiology for his entire 
professional life. Mann did not believe that the portal blood had 
special qualities important for liver health, mainly because firm 
evidence to support the presence of such portal substances had 
h · '22 23 M .. d never been unearthed by others or by 1m. .' ann envlslone 
the liver mass as a byproduct of, or a kind of encrustation upon, 
its complex capillary bed, which in turn was controlled solely by 
the volume of blood presented to it. He wrote, "restoration of the 
liver depends ... upon the flow of portal blood through the or-
gan [liver] and ... the primary stimulus is the [quantity oll the 
portal blood itself.":.!2 This was the flow hypothesis. 
TilE FLOW HYPOTHESIS 
The experiments of Mann merely failed to support the possi-
bility that the portal blood has special qualities; Mann was 
never able to produce evidence to contradict what later came to 
be known as the hepatotrophic concept. In contrast, the studies 
by Child et al.,2.1 using portacaval transposition in ~ogs as the 
experimental model, were erroneously but gen~rally fn~erpre~ed 
as crucial evidence favoring the flow hypothesIs and dIsproving 
the hepatotrophic concept. By replacing the diverted splanchnic 
venous blood with an inflow from the inferior vena cava to the 
hepatic end of the portal vein (Fig 4), Child et aI. avoided most 
of the adverse effects of Eck's fistula. These studies24 and those 
of Fisher and his associates25. 26 gave firm support to the concept 
that the quality of portal venous inflow was not a prime deter-
minant of hepatic structure, function, or the capacity for regen-
eration. In some of Fisher's experiments involving end points of 
regeneration, the diverted portal blood was replaced by arterial-
izing the hilar portal stump.25 
Subsequent workers accepted that the quantity of total hepatic 
blood flow was the main consideration in supporting liver 
health. This acceptance was maintained in spite of the demon-
stration that canine livers after venous transposition actuall1s 
showed centrilobular atrophy,24 and major deglycogenation,27. 8 
and thus were not in fact normal. The con census favoring the 
Aow hypothesis was an uneasy one, and in 1961 Bollman, one of 
Mann's younger associates, wrote, "In the 83 years since it was 
first reported the Eck fistula has been reasonably successful in 
hiding its secrets as well as giving rise to many additional ques-
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Fig 4.-The operation of portacaval transposition. The procedure is a standard 
laboratory experiment but it has been used clinically to treal two patients with gly-
cogen storage disease. Note that the central portal vein is revascularized with vena 
caval blood. (From Starzl et al. 28 Reproduced by permission.) 
tions fundamental to an understanding of the functions of the 
intestine, liver and brain." 
THE HEPATOTROPHIC HYPOTHESIS FROM STUDIES OF LIVER 
TRANSPLANTATION 
The Aow-oriented view held sway until it was definitively 
challenged by investigations that originated in studies of exper-
imental liver transplantation. These studies were thoroug~ly re-
viewed almost 15 years ago. 29 The most illuminating observa-
tions were made when an extra liver was transplanted to an 
ectopic site without disturbing the animal's own liver. It was 
noted that auxiliary hepatic homografts underwent remarkable 
atrophy30 if they were revascularized by a technique described 
by Welch. 31 With Welch's method, the auxiliary liver was Dp~o­
vided with an arterial blood supply from the aorta or an IlIac 
artery, and the portal vein was anastomosed to the inferio~ vena 
cava (Fig 5). The atrophy of the auxiliary organ was rapId and 
extreme (Fig 6), even though the bl~o? s~ply was a~alogous to 
that in Child's portacaval transpOSitIOn. One pOSSIble expla-
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Fig S,-Auxiliary liver transplantation in dogs by a modification of Welch's original 
technique. Note that the reconstituted portal blood supply is from the distal inferior 
vena cava. (From Starzl et al.'o Reproduced by permission.) 
nation advanced was that the animal's own liver, in situ, which 
was perfused first by splanchnic venous blood, was extracting a 
disproportionate share of unspecified hepatotrophic substances 
and that the auxiliary organ atrophied because of its disadvan-
taged competitive situation. :10 
The hypothesis was supported by Marchioro and his associ-
ates,:l:l who showed that transplant atrophy could be prevented 
by diverting the non hepatic splanchnic venous blood away from 
the host liver and through the graft. The atrophy then affected 
the native liver. Confirmatory observations were reported by 
"1"1 Df~ 35 Thomford;' Halgrimson; and Tretbar' and their associates. 
Thomford et al.:I:1 showed that atrophy in Welch's auxiliary hom-
ografts could be prevented in recipients that had undergone im-
munosuppression, if host livers were removed within a few days 
after transplantation, and Tretbar et al. 35 and Halgrimson et 
al.:14 demonstrated that the shrinkage could be reduced by di-
verting portal blood away from the host liver, even though the 
700 
Fig S.-An auxiliary homograft (right) and the recipient dog·s own liver (left) 45 
days after transplantation. Note the well·preserved but dimensionally reduced gen· 
eral structure of the homograft. At the time of transplantation, both the host organ 
and the transplant had been about the same size. (From Starzl et al. JO Reproduced 
by permission.) 
portal blood was not directly channeled through the transplant. 
Observations by Sigel and his associates36. 37 with hepatic auto-
grafts implanted on intestinal vascular pedicles or directly re-
vascularized in the neck could be interpreted in the same way. 
The transplant preparations that made possible the foregoing 
observations had two serious flaws; these flaws prevented inves-
tigators from coming to definitive conclusions about the patho-
genesis of the atrophy. First, the total flows delivered to the two 
coexisting livers were often different. Second, there was by defi-
nition another inherent inequality of the two organs: the homo-
graft was usually under immunologic attack, despite host im-
munosuppression,29,30 whereas the animal's own liver was not. 
Consequently, other experiments were undertaken that were de-
signed to circumvent one or both of these deficiencies. 
One preparati?n not !nvolvin~ transplantation .was used, by 
Mal'chioro and hIS assoclates·18, 3 and termed a spltt (or partlalJ 
transposition. In essence, the procedure entailed the creation of 
two liver sections that differed only in the nature of their portal 
venous inflow. Splanchnic venous blood was provided for one 
portal branch to the liver, whereas the other portal branch was 
supplied with blood from the inferior vena cava (Fig 7); flow to 
the liver tissue given vena caval blood was at least as great as 
that on the opposite side.39 Later, Price,40 Lee,ll and Chandler"2 
and their associates performed analogous experiments, either 
with canine partial hepatic autografls or with isografl.s of inbred 
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Fig 7.-The operation 01 partial (split) transposition in dogs. Note thaI one 01 Ihe 
main portal veins (left in A, right in B) retains Ihe natural splanchnic flow and that 
the other one receives the total input of the suprarenal inferior vena cava. (From 
Mzrchioro et al. J9 Reproduced by permission.) 
rat livers. All of these experiments showed hypertrophy in the 
hepatic tissue that was perfused with splanchnic blood, and 
atrophy in the hepatic remainder, which was provided with sys-
temic venous inflow. 
The impressive evidence obtained from 1964 to 1972 that por-
tal hepatotrophic factors were physiologically important was not 
taken seriously by skeptics because of the failure to identify the 
mysterious portal blood substancefsl. One possibility sometimes 
cited as an explanation for a specific benefit of portal blood was 
a high portal vein oxygen concentration. This concept was incor-
rectly attributed to Blalock and Mason,43 as we have pointed out 
elsewhere. 44 When the oxygen content of splanchnic venous 
blood actually was compared to the oxygen content of inferior 
vena caval blood in unanesthetized awake dogs long after por-
tacaval transposition, such an "advantage" of higher portal ox-
ygen content did not exist. 44 
THE HORMONAL NATURE OF THE HEPATOTROPHIC 
SUBSTANCES 
FnOM DOUBLE LIVER EXPERIMENTS 
In 1973, the explanation was advanced that endogenous hor-
mones returning from the splanchnic organs were the principal 
hepatotrophic agents. 45 This conclusion was based partly on the 
histopathologic results from another kind of "double liver" 
model which was used in an effort to pinpoint the splanchnic 
organs from which the so-called hepatotrophic factors came. 
Marchioro et al. used this approach in one of their auxiliary 
homograft experiments,32 and Pouyet et al. modified the ap-
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proach in a nontransplantation model. 46 The most useful prepa-
ration was one in which blood returning from the pancreas, duo-
denum, stomach, and spleen passed to one portion of the liver 
while the other liver portion was perfused with venous blood 
returning from the small intestine (Fig 8).45 
The results were unequivocal. The liver portion perfused with 
blood returning from the upper abdominal viscera remained 
healthy. In contrast, the liver portion provided with intestinal 
blood became atrophic, deglycogenated, and infiltrated with fat. 
The organelle structure of the atrophic portion was like that af-
ter portacaval shunt, including disruption and depletion of the 
RER. 
An accurate way to quantify hepatocyte size was developed for 
such experiments.45 With light microscopic tracing, hepatocytes 
were drawn onto a standard thickness paper and weighed. The 
weights were called size units. The cell size data could then be 
summarized in graphs or tables. In Figure 9, the right lobar he-
patocytes, which had pancreaticoduodenosplenic input and so 
had an obvious advantage, are compared with those on the left, 
which were fed with intestinal venous return. The foregoing his-
topathologic observations made the pancreas suspect as a major 
hepatotrophic source and insulin the most likely principal he-
patotrophic substance. 
The morphological observations were bolstered by the so-
Fig B.-Splanchnic division experiments. In these dogs, the right liver lobes re-
ceived venous return from the pancreaticogastroduodenosplenic region. and the left 
liver lobes received venous blood from the intestines. A, nondiabetic dogs; e, al-
loxan-induced diabetic dogs: C, dogs with total pancreatectomy. (From StaTZ! et 
al. 47 Reproduced by permission.) 
, -;-
( <./ 
A. B. 
PANCR[ATECTOM( 
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LEFT 
Fig g.-Hepatocyte shadows traced during histopathologic examination. These 
were later cut out on standard paper and weighed as an index of hepatocyle size. 
The right lobes with Ihe large hepatic cells received venous blood from the pancreas, 
stomach, duodenum, and spleen. The relatively shrunken left lobes with the small 
hepatocytes received intestinal blood. (From Starzl et al. 45 Reproduced by permis-
sion) 
called double liver preparations (see Figs 7 and 8) by numerous 
biochemical studies in the two liver sides which included glyco-
gen, glucokinase, cyclic AMP, active phosphorylase, and lipids. 45 
There were major differences in the liver segments according to 
the nature of the portal venous inflow. The details of the bio-
chemical disassociation are beyond the scope of this review, but 
the reasonable inference was that the two liver sides were living 
in different metabolic worlds, in which hormone control was the 
dominant factor. Futhermore, the nature of the biochemical dif-
ferences suggested that endogenous insulin, which was being ef-
ficiently extracted by the first liver tissue to which it was ex-
posed, played an important role. The significance of endogenous 
insulin was further highlighted when the advantages enjoyed by 
the lobes perfused by splanchnic venous blood were found to be 
greatly reduced, although not eliminated,l7· 47. ,If! by either total 
pancreatectomy or alloxan-induced diabetes (see Fig 8). These 
investigations, while emphasizing the role of insulin, showed 
equally clearly that non pancreatic hormones or other substances 
also contributed to the total hepatotl'ophic effect of splanchnic 
venous blood. Although the influence of these extrapancreatic 
factors remains unchallenged, they have not been identified. 
Complicated though they were, the double liver segment mod-
els were crucial to an understanding of the enigmatic Eck fis-
tula. If insulin was a vital hepatotrophic factor, the reason for 
its unmasking by the double liver fragment experiments became 
understandable. The well-known efficienc~ of insulin removal 
during a first pass through hepatic tissue4 -51 made the insulin 
relatively unavailable for a second liver or a liver segment and 
thus exaggerated the effect of portal blood deprivation. 
At the same time, the protection afforded after portal diver-
sion by flow augmentation procedutes such as Child's portacaval 
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transpositionl4 or Fisher's port,al arterialization:!5 was explained. 
If insulin and other hepatotrophic substances were bypassed 
around a single liver they would be returned to it in a diluted 
form in direct relation to the total hepatic blood now, which 
these procedures increased. 
FROM HOHl\IONE INFUSION EXPERIMENTS 
Eventually it became necessary to return full cycle back to 
experiments utilizing Eck's fistula. If the secrets of Eck's fistula 
were explained mainly by the deprivation of the liver of direct 
access to endogenous insulin, the experiment shown in Figure 
10 should have been a direct test of that hypothesis. Nonhypo-
glycemic infusions of insulin, glucagon, and other substances 
were made for 4 days into the ligated left portal vein after con-
struction of Eck's fistula. lO• II The experiment was designed to 
evaluate any direct protective effect of hormones on the left lo-
bar hepatic tissue as well as to assess a spillover effect on the 
right lobes after recirculation. The results were unequivocal. In-
sulin greatly reduced the atrophy that otherwise halved the size 
of the cells within 4 days, and it preserved the hepatocyte ultra-
structure. In small doses glucagon did not potentiate the action 
of insulin and in large doses it may have reduced the insulin 
benefit. Glucagon alone, in large or small doses, had no ef-
fect.lo. II 
Fig 10.-Experiments In which Eck's fistula is constructed and postoperative in-
fusions of hormones are made inlo Ihe left portal vein. (From Starzl et al. " Repro-
duced by permission.) 
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The effect of insulin on hepatocyte proliferation in these ex-
periments was also striking. After construction of Eck's fistula, 
the mitotic rate was already increased to about three times nor-
mal (from 1.6 to 4.811 ,000 hepatocytesl. Insulin more than tri-
pled this cell renewal, with no spillover to the contralateral 
lobes. Glucagon alone had no effect, nor did it potentiate the 
action of insulin. to. )) 
FHOM EVISCEHATION AND HEPATOCYTE CULTUHE EXPEHlt-.IENTS 
Thus, relative "hepatic insulinopenia" was established as the 
most important element in the liver injury of Eck's fistula. How-
ever, the clarity with which insulin has emerged as the principal 
portal hepatotrophic substance has not diminished interest in 
the search for contributory hepatotrophic factors. The incom-
plete insulin protection observed in our infusion experiments 
was interpreted as a reflection of the existence of ancillary sub-
stances.IO, I) Evidence that there are multiple hepatotrophic fac-
tors has been uncovered with all of the experimental models 
used by us. 10, I). 17, 45. 47, 411. 52.53 
However, the probability that there is multifactorial control of 
hepatocyte integrity has not deemphasized the central role of 
insulin in maintaining liver cells. This was recently demon-
strated once again in animal studies after all the nonhepatic 
splanchnic viscera had been removed, including the pan-
creas. f,2.5:1 The intraportal infusion of insulin alone prevented 
most of the atrophy and other structural deterioration of hepa-
tocytes that otherwise occurred, and it preserved the rate of 
spontaneous liver cell renewal, which was otherwise depressed. 
The hepatic protection in eviscerated animals52 was almost iden-
tical to that observed with intraportal insulin therapy after por-
tacaval shunt 10, I) and was indistinguishable from the hepatic 
protection provided by insulin in diabetic rats. 54 
In hepatocyte tissue culture systems, many investigators have 
described analogous insulin effects. 55-58 The role of insulin in 
maintaining heEatocyte mitochondrial metabolism has also been 
emphasized.',9,6) No potentiating effect of glucagon has been 
demonstrated in any of these models. 
FUNCTION OF THE ECK FISTULA LIVER 
BIOCHEMICAL PAHAt-.IETERS 
Liver function after construction of Eck's fistula, or after the 
better tolerated portacaval transposition of Child et a\.,24 was 
long thought to be essentially normal, the main defect being in-
efficient clearance of ammonia.6), 62 Only in the last 10 or 15 
years has it been realized that subtle but cumulatively massive 
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changes in hepatic function are caused by portal diversion and 
for the most part by the bypassing of endogenous insulin. These 
alterations are so sweeping that an all-inclusive description 
would require a discussion of virtually every facet of hepatic 
physiology and metabolism. 
The morphological counterpart of (and explanation for) such 
major changes in hepatic metabolism was described in an earlier 
section, when we noted that a relatively specific effect of porta-
caval shunt is the qualitative and quantitative loss of RER and 
its linin!f~ollribosomes (see Fig 3). Since·RE"R-j"s- the "factory" 
of the cell, :1, 4 a consequent reduction in many biosynthetic pro-
cesses would be expected. Numerous studies have verified this 
hypothesis. We will comment here on effects chosen because of 
their clarity or because of their probable or proved clinical sig-
nificance. 
The effect of portal diversion on hepatic lipid metabolism has 
been unusually well studied. Since portacaval shunt reduces the 
serum concentration of cholesterol in animals)7,6" and in hu-
mans,20,66 it was natural to wonder if this peripheral antilipi-
demic effect could be explained by a reduction in hepatic lipid 
synthesis. In our initial investigations of this possibility, we 
demonstrated reductions of more than 8Wk in canine hepatic 
cholesterol and triglyceride synthesis. 17 Although a similar dim-
inution in cholesterol and/or l~oprotein synthesis was confirmed 
in rats,67-69 dogs,iO swine,71- . and baboons/o not all workers 
could verify these findings. The rigorously controlled studies in 
rats by Proia et al.,68 which are the only reported animal exper-
iments concerning Eck's fistula and lipid synthesis in which 
body weights were maintained or increased postoperatively, 
have done much to explain the discordant reports. In addition to 
demonstrating a reduction in cholesterol synthesis, Proia et al. 68 
made the crucial observation that the total body cholesterol was 
diminished after portal diversion. As will be discussed later, 
data on hepatic lipid synthesis also are available from patients 
treated by us with portacaval shunt for familial hypercholester-
olemia. It may be considered proved that lipid homeostasis is 
altered to an extraordinary degree by portacaval shunt, the re-
duction in hepatic lipid synthesis being the greatest change. 
It has been equally well established that bile acid synthesis is 
greatly reduced by portacaval shunt. 6A,74-76 Another synthetic 
pathway that has been well studied after portal diversion is the 
hepatic urea (Krebs-I1enseleit) cycle, which has been shown by 
Reichle et al. to be depressed by Eck's fistula in rats 77 and 
dogs;8; they demonstrated a reduction in several of the enzymes 
involved in this metabolic pathway. 
As detailed studies are made of other hepatic synthetic or 
metabolic processes after portacaval shunt, it will not be sur-
prising if all are found to follow the same pattern. This possibil-
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ity is supported by many studies during the past 15 years that 
have shown that portacaval shunt lowers the activit~ of the ~e­
patic microsomal mixed-function enzyme system. 9-llfi ASIde 
from illustrating the principle of a wide-ranging decline in he-
patic synthesis functions after portacaval shunt, these. observa-
tions are of potential specific importance because the mIcrosomal 
mixed-function enzyme system, for which multiple cytochrome 
P-450 and P-448 species serve as terminal oxidases, metabolizes 
a variety of drugs and foreign chemicals as well as endogenous 
compounds such as steroids and faUy acids. The depression of 
this enzyme system with its broad-ranging functions would re-
late to enormous numbers of metabolic effects of portal diver-
sion. 
There is no reason to suspect that depression of the microso-
mal mixed-function oxidase system is caused by factors other 
than the loss of the hormone-rich splanchnic venous blood. Proia 
et al.H6 have shown that the poor diet and weight loss in animals 
with Eck's fistula are not responsible. Furthermore, Pector et al. 
have shown that the hepatic alterations in the mixed-function 
oxidase system are the same whether the tied-off central portal 
vein is arterializedllll or revascularized with systemic venous 
blood using the transposition technique. Bl These latter experi-
ments showed that the mere restoration of the "wrong" kind of 
hepatic blood flow could not prevent the changes which are sf.e-
ciflc to portal diversion. The results of Pector's experimentsR .81 
were predictable from the earlier work of Marchioro et al.,39 in 
which flow augmentation with systemic venous or arterial blood 
did not prevent atrophy of liver tissue that had lost its portal 
venous inflow. 
The most important single factor in the etiology of the compli-
cations of Eck's fistula is depriving the liver of direct access to 
endogenous insulin. In accordance with this concept, Kato f!7 has 
shown that the activity of the mixed-function oxidase system is 
depressed in rats with alloxan-induced diabetes in the same way 
as it is depressed by portacaval shunt. 
QUESTIONS OF Il\IMlINOLO(;Y 
It can be considered firmly established that portacaval shunt 
causes many alterations in hepatic metabolism. Far more spec-
ulative is the possibility that immunologic function may be 
changed. . 
Studies during the last 20 years have suggested, or have 
claimed to demonstrate that there is a reduced response to an-
tigens introduced .into the portal ~s compared to theUi~~onseKto 
those introduced mto the systemic venous system. Partial 
removal of the antigens by the liver and thus a diminished host 
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reaction to their presence has been the most common explana-
tion. Alternatively, some investigators have suggested that an-
tigen delivery to the liver via the fortal vein could contribute to 
the induction of tolerance.RB.96-9 Many of these investigators 
have envisioned the normal liver as a barrier against, or as a 
modulator of, a host of environmental antigens, toxins, or car-
cinogens from the gastrointestinal tract which could injure the 
whole animal or the liver itself. Obviously, such a first-pass 
screening function would be mechanically disconnected by por-
tacaval shunt. In addition, the depression of the hepatic mixed-
function oxidase system after portacaval shunt, described in the 
preceding section, could further jeopardize such a guardian role. 
The expectation that the liver could remove or inactivate an-
tigens has led to efforts to create "privileged" situations with a 
variety of homografts. The organs used ,for such test systems 
have included kid neys99-105 and hearts. 106 The venous return of 
the transplant in these preparations has been directed through 
the liver via an anastomosis to the portal vein (Fig 111. In ad-
. . . . I II 107 1 Of! d th' d . II 1119 h ditlOn, pancreatIc IS et ce s . an para yrOl ce save 
been transplanted directly into the portal circulation or into the 
liver. 
The results have been variable. In rats, all reports have de-
scribed a protective effect of the portal site, but usually only 
Fig 11.-Experimental models used in dogs and pigs to test the hypothesi~ th?t 
the liver can remove transplantation antigens. A, orthotopic renal transplantation In 
which the venous return was into the inferior vena cava. B, orthotopic transplanta· 
tion. but venous return is into the portal vein. (From Mazzoni et al. 110 Reproduced 
by permission.) 
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h · 'b'l't b . 105.106.108. IIJ9 M zzonl' et across easy Istocompatl I I Y arners. a.
al. lO:I· 104 had similar positive res~lts in pig kidneys, but It?elr 
findings were not confirmed by Hickman and Terblanche or 
by later studies by Mazzoni himself. 110 Barker and Corriere,9!! 
Fukuda et at., lUll and May et al. 102 saw no amelioration of the 
rejection of primary canine kidney homografts drained through 
the portal vein. 
The concept of hepatic clearance of antigens was thought by 
us to be so important that Mazzoni, one of the main proponents 
of this hypothesis,lo:1. 104 was invited to our laboratory in 1976 
and 1977 to verify his own earlier observations. He was unable 
to do so. When he transplanted kidneys into mongrel dogs or 
into pigs so that the renal venous drainage was into the portal 
system of the hosts (see Fig 11), graft survival was not signifi-
cantly increased compared to graft survival when renal venous 
d . . t th I \(J ramage was In 0 e vena cava. 
On the basis of Mazzoni's later investigations, II(J it seems un-
likely that any specific benefit from organ transplantation to the 
portal vein can be expected in patients. The question that re-
mains is whether the portal site allows amelioration of rejection 
in rats and mice. It is unlikely that the issue of "portal" implan-
tation will ever be important in transplantation, but the in-
triguing possibility that the liver is a subtle modulator of im-
mune events has not been disproved. For the moment, however, 
it must be concluded that there is no sound factual basis for this 
concept and that a change in immunologic reactivity is not, 
therefore, an expected consequence of portacaval shunt. 
RELEVANCE OF ANIMAL STUDIES TO HUMAN 
PHYSIOLOGY 
The histopathologic alterations in, and changes in function of, 
the liver caused by portacaval shunt are essentially the same in 
rats, swine, dogs, monkeys, baboons, and humans. III However, 
until about 30 years ago it was not known whether the lethal 
consequences of portacaval shunt represented more than a spe-
cies peculiarity of the dog. Until then, Eck's fistula had not been 
evaluated in other animals. In humans, portacaval shunt had 
not been performed on anybody who had a previously normal 
liver, and consequently any opinions about the metabolic effects 
of Eck's fistula in man were purely speculative. The dearth of 
information began to end with the classic clinical articles of 
McDermott et aL, I J 1.112 which seemed to be confirmed by 
HubbardJl3 a few years later. Unfortunately, misinterpretation 
of the observations in these reports actually delayed an under-
standing of the physiology of human portacaval shunt for almost 
two decades. 
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THE McDERMOTT-HuBBARD ARTIFACT 
McDermott et al" lI . 112 and Hubbard l13 each reported on two 
patients who had carcinomas of the head of the pancreas and 
grossly normal livers except for biliary obstruction. In order to 
perform pancreaticoduodenectomy, it was necessary to resect the 
portal vein, and in all four patients, the end of t~e transec~ed 
superior mesenteric vein was anastomosed to the sIde of the 111-
ferior vena cava. 
The results were devastating. Within a few weeks or months, 
all four patients developed episodic hepatic encephalopa~hyI 
malnutrition, fatty infiltration of the liver, and hypoa~bum1l1e­
mia. When the patients died, 4-20 months postoperatIvely, all 
were tumor free. It was concluded that these were examples of 
Eck's fistula in humans with normal livers, that humans were 
even more sensitive than dogs to the metabolic complications of 
Eck's fistula and that the ability of patients to tolerate portal 
diversion w~s inversely related to the quality of preexisting he-
patic function. 
None of these conclusions was valid. The errors were caused 
by the investigators' failure to appreciate that the o~eratiKons 
were not pure Eck's fistulas. In addition to the portal dIverSIOn, 
all four of the patients also had removal of variable amorl~ts of 
the pancreas, which later investigations proved to be the s1l1gle 
most important source of hepatotrophic substances. Eventually 
it was realized that man is less, not more, susceptible than ex-
perimental animals to the metabolic complications ?f Eck's fis-
tula. Finally, it is not true that portacaval shunt IS tolerated 
best in patients with the worst hepatic disease; the converse is 
true. 
TIlE SPECIES FACTOR IN ENCEPHALOPATHY 
The weight loss, alopecia, and encephalopathy first described 
in dogs after portacaval shunt construction have been less se-
vere or inconstant in rats. 114- 117 In swine, some investigators 
have been able to carry out studies for 2-4 months after porta-
caval shunt construction,71-73 but others have found the opera-
tion to cause hepatic failure and encephalopathy within 
days. 118. JI9 Subhuman primates including Rhesus l20 and Ma-
caca mulatta l21 monkeys as well as bahoons,l7· IR may develop 
the Eck fistula syndrome in such a fulminant form as to make 
it difficult to perform metabolic studies. The brains of the ba-
boons have shown the same glial proliferation and central pon-
tine myelinolysis l8 seen in rats ll and monk eys l22 after portal 
diversion. 
Fortunately, the remarkable encephalopathic complications 
711 
produced after the subhuman primate operations have not been 
duplicated in humans with previously normal livers. The human 
experience with pure Eck's fistula in the presence of normal he-
patic function has been in patients with types I, III, and VI gly-
cogen storage disease IGSDI or familial hypercholesterolemia 
(FIll. 
The patients with GSD generally tolerated portacaval shunt 
well in spite of the fact that their well-functioning livers usually 
had significant preexisting structural abnormalities. 19. fir, Of 
nine GSD patients followed by us for 4Y4 to 191/~ years after por-
tal diversion, only one developed hepatic insufficiency and en-
cephalopathy-8 years after portacaval shunt. This girl was suc-
cessfu lIy treated with orthotopic liver transplantation In; it was 
possible to take down the portacaval anastomosis and use the 
portal vein to revascularize the new liver. None of the other pa-
tients with GSD treated with portal diversion are known to have 
developed encephalopathy. 
The picture was even clearer in patients who had portacaval 
shunts constructed for FH. Characteristically, patients with this 
disease start with completely normal liver structure and normal 
hepatic function. Only one of our 13 f,atients, and none of the 26 
others reported from other centers,l 4 had overt manifestations 
of the Eck fistula syndrome on follow-up of 1 to nearly 10 years. 
The exception in our series was a 3-year-old girl who had a sin-
gle episode of unconsciousness 9 months after portacaval shunt 
construction at a time when the blood ammonia was 85 l.lg/dl 
(normal in that laboratory, <55 J.lg/dll. Encephalopathy was ac-
cepted as the diagnosis because no other explanation was found. 
The child is well on a low-protein diet. 
The histopathologic changes caused by portal diversion in the 
livers of these patients (see Fig 3) have been indistinguishable 
from those in animals.:'w. 124 It is noteworthy that blood ammonia 
levels, when measured, have always increased to or beyond the 
upper limits of normall~4; low-grade elevations of serum trans-
aminase and alkaline phosphatase levels have been common. 
Although the patients have been clinically well and on a normal 
diet after portacaval shunt construction, there has been no rea-
son to doubt that their hepatic function has been impaired. Nev-
ertheless, their behavior and physical development have not 
been obviously altered. 
The only other use of portal diversion in the presence of a 
normal or nearly normal liver has been in patients with esopha-
geal varices from extrahepatic portal venous obstruction Ipresi-
nusoidal block). The thrombosed portal vein in many such pa-
tients is replaced with a multitude of collaterals which are 
frequently so well developed that they have been referred to col-
lectively as "cavernous transformation." It has been suspected 
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for a long time, and unequivocally demonstrated in a recent 
publication of Warren et al.,125 that flow in the collnterals is 
hepatopetal and thus important in perfusion of the liver with 
hormone-rich splanchnic blood, albeit by circuitous routes. If a 
sound portal-systemic anastomosis can be constructed (usually 
with splenorenal, cavomesenteric, or makeshift shunts), control 
of variceal hemorrhage is almost always achieved. At the same 
time, the collateral splanchnic venous flow to the liver described 
above is "stolen" from the Iivel- through the shunt. f~:; 
In spite of this physiologic penalty, clinical results after tech-
nically satisfactory shunt procedures usually have been good, as 
exemplified by a recent report of Grauer and Schwartz. 126 Of 
their 19 patients, none developed liver failure or encephalopathy 
on follow-up as long as two decades. The observations were con-
sonant with those of previous workers. 127. 128 
Even more reassuring were the results obtained in the French 
hepatology unit of Alagille and summarized by Alvarez et a\.129 
Seventy-six children with portal obstruction had portal-systemic 
shunts (32 central splenorenal, 32 Marion mesocaval, 6 interpo-
sition mesocavaI. 3 makeshift, 2 distal splenorenal, 1 portaca-
vall. Seventy of the shunts remained patent. Although blood 
ammonia levels were slightly elevated, none of the patients de-
veloped encephalopathy, as judged by neurologic examinations 
and electroencephalograms every 6-12 months, and by analysis 
of academic performance. Physical growth was not interrupted; 
in fact, it was accelerated. 
Nevertheless, hepatic dysfunction and encephalopathy havc 
been reported by Mikkelsen et a\.130 with or without portal di-
version in patients with extrahepatic portal block; in two such 
patients Warren et a\.12S achieved reversal of encephalopathy 
after disconnecting the portal-systemic shunts and restoring the 
hepatopetal flow. 
Voorhees et a\.131 have added the chilling notc that patients 
treated with portal-systemic shunt for extrahepatic portal block 
at Columbia University, New York, have had a high incidence 
of psychological and psychiatric perturbations, which they sug-
gested might be occult manifestations of encephalopathy. These 
latter conclusions have not been verified, and careful psycholog-
ical and intelligence examinations in patients with familial 
hypercholesteremia 124 have not turned up anything resembling 
Voorhees' observation. 
The resistance of man to encephalopathy aller portacaval 
shunt has not been explained satisfactorily. One possibility is 
that the natural diet of humans is more compatible with the 
depressed hepatic function of Eck's fistula than the diet of some 
of the animal species. In various animals, the clinical manifes-
tation of hepatic encephalopathy can be forestalled or ameJio-
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rated with special low-protein diets, and obviously the same 
kind of dietetic management is a standard reaction if hepatic 
encephalopathy occurs in patients. 
THE HUMAN ECK FISTULA SYNDROME VERSUS PREEXISTING 
LIVER FUNCTION 
The McDermott-Hubbard artifact led to speculation, if not to 
an absolute conviction, that the risks of the Eck fistula syn-
drome in humans were proportionate to the quality of preexist-
ing function, being greatest with a completely normal liver. It 
was rationalized that severely diseased livers that had already 
lost hepatopetal portal flow to collaterals would not be much fur-
ther affected by a portacaval shunt and that such livers would 
have had compensatory increases in hepatic artery flow. In con-
trast, the argument continued, normal or near-normal livers 
that still retained significant portal venous flow would sustain a 
major insult by abrupt diversion of this flow. 
It would be a perversion of scholarship to cite statements by 
distinguished hepatic surgeons who have defended this kind of 
sophistry during the last 30 years. Suffice it to say, during much 
of this same period the inescapable conclusion from clinical ex-
perience with various shunting procedures has been the opposite 
of the foregoing hypothesis. For two decades, the risk in most 
patients being considered for portal diversion has been strati-
fied, by the so-called Child classification, according to the qual-
ity of hepatic function. I:J2 Patients with the best hepatic function 
are placed into Child class A, those with the worst function are 
placed into class C, and the others are placed in class B. All 
major studies that have taken into account such disease staging 
have shown the best results after portal-systemic shunt opera-
lions to be in class A patients and the worst to be in class C 
patients. Parenthetically, the Child class A patients are the 
most apt to have residual hepatopetal flow, although the associ-
ation is too imperfect to be useful in predicting the out-
come.I:!:!. 1:!4 
ECK'S FISTULA FOR METABOLIC OBJECTIVES IN HUMANS 
Benefits have been seen after end-to-side portacaval shunt in 
patients with three inborn errors of metabolism: glycogen stor-
age disease IGSO), familial hypercholesterolemia (FH), and 
ol-antitrypsin deficiency. In each instance, the amelioration of 
symptoms has been the tradeoff for the hepatic damage caused 
by putting the liver into the portoprival state. 
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GL YCU(a,:N STOIL\(;E DISEASE 
When portal diversion was first performed for GSD almost 20 
years ago,2R the rationale for the procedure was different from 
our understanding today. In 1963 it was hoped that by short-
circuiting splanchnic venous blood around the liver, glucose 
would be made more readily available to peripheral tissues, with 
relief of hypoglycemia; it was further expected that the liver 
would becoincidentalll deglycogenated, since this had been ob-
served in animals.n . 2 As this monograph has made clear, the 
consequences of portacaval shunt are more subtle and wide 
ranging than the simplistic view suggested. 
The first patient who had total portal diversion is still alive 
almost 20 years after portacaval transposition. She had type III 
GSD. A patient similarly treated by Riddell et a1. 135 also sur-
vived long term. Our second patient died 2 days after portacaval 
transposition, probably because the liver could not transmit the 
high-volume How of the inferior vena cava. 19 Simple end-to-side 
portacaval shunts were used in all of the eight subsequent pa-
tients in our series, 19.66 of whom seven are alive after S1;~ to 
more than 10 years. 
The amelioration of symptoms of GSO was confirmed by other 
observers, whose cases have been summarized b~ US I9. (i6 and by 
other reviewers. 136.137 In 1972, Folkman et al.I 8 added an im-
portant therapeutic dimension by showing how preoperative 
parenteral hyperaJimentation could reduce the operative risk by 
normalizing preexisting hepatomegaly, acidosis, and othel' ab-
normalities, including hjPerlipidemia. In an extension of this 
concept, Greene et a1. 13 and Crigler and Folkman l10 showed 
that continuous or frequent feeding (including overnight ali-
mentation) is more than an alternative to portacaval shunt 
in the treatment of this disorder-it is, rather, the ther-
apy of choice. Nevertheless, follow-up of the early patients 
with GSO treated with portal diversion is of considerable 
interest. 
The ages of our ten patients, types of disease, and symptoms 
are summarized in Table 1. Type I disease (glucose-6-phospha-
tase deficiency) was the most common indication for treatment, 
with type III disease (amylo-l,6-glucosidase deficiency) being a 
distant second. 
Metabolic Effects 
After portal diversion, most of the children who had preexist-
ing hypoglycemia did not have relief of this symptom or the re-
lief was not complete. Thus, night feedings usually had to be 
continued. Studies of plasma insulin and glucagon in several of 
these patients revealed the pattern shown in Figure 12. The flat 
peripheral insulin curves typical of type I GSO l41 became ele-
vated after portacaval shunt, and there were smaller increases 
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in glucagon. The glucose tolerance curves were much the same 
before and after operation. 
Liver glycogen concentrations in those of our patients who 
later had liver biopsies were not changed, nor were the mea-
sures of enzyme activity. It is of interest that Corbeel et al.l37 of 
Belgium found a striking increase of active glucose-6-phospha-
tase after portacaval shunt in a child with type Ib GSD. It was 
speculated that the portal diversion had unmasked a nonfunc-
tional glucose-6-phosphatase by improving the defective trans-
port of this enzyme across microsomal membranes. 
In spite of failure to alter the hepatic glycogen concentration, 
19. (i6 the liver size in several of our patients and those reported 
by others underwent a very obvious reduction, as measured by 
liver scan planimetry. Even if obvious gross shrinkage did not 
occur, postoperative bio~sies always showed a diminution in in-
dividual hepatocyte size 9.66 similar to that produced in animals 
by portacaval shunt. 
In contrast to the incomplete relief of hypoglycemia, all com-
ponents of the hyperlipidemia which is a characteristic of the 
type I disease were profoundly and permanently relieved (Fig 
13). Correction of other metabolic defects was observed, includ-
ing abnormal bleeding, uric acid elevations, and abnormal cal-
cium metabolism. 19, 66,135-138 
Growth 
All ten of our patients had growth retardation before porta-
caval shunt, Afterward, height increases, which in most cases 
had virtually ceased, occurred during the first postoperative 
year at the rates listed in Table 2, approximately 0.5 cm/month. 
TABLE 2.-GRowTII RATE AND Cl~fmifCAqflkp AFTER PORTAL DI\'EHSION r(Jn 
GL YCOGEN STORAGE DISEASE 
PATIENT 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Mean 
GROWTH RATE 
(em/mo. over 
40-120 mo.) 
0.49 
Operative death 
0.50 
0.28 
0.53 
0.62 
0.50 
0.49 
0.88 
0.4 
0.54 
COMPI.ICATIONS 
Macroadenomatosis 
Died 4Y. years after shunt; primary 
pulmonary hypertension, Nil" ~ 85, 
macroadenomatosis 
Renal artery stenosis surgica II)' corrected 32 
months after shunt 
Macroadenomalosis; liver transplantation 
after 8'12 years 
Renal stone 2 months after shunt; mild 
arterial hypertension, macroadenomatosis 
Growth cessation after 2 years 
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The same phenomenon has been described in almost all of the 
other repO/-ted cases. 
Quantitative measures of growth were obtained with radio-
graphic techniques. I!J An example of the results is shown in Fig-
ure 14. Comparison of the wrists and hands in this 7-year-old, 
stunted child before and Ill/;! months after operation shows the 
phenomenal elTect of bone age doubling. In addition to the 
changes in bone size, mineralization occurred, and new wrist 
bones apreared. Circulating somatotropin in these patients was 
normal. I The growth spurts may have been at least partially 
attributable to the increased insulin distribution to the periph-
ery, mentioned earlier (see Fig 12), since insulin has been rec-
ognized as a major growth hormone, comparable in potency to 
somatotropin. 
Morbidity {rom Portacaml Shunt 
The patient who exhibited hepatic encephalopathy 8 years af-
ter end-to-side portacaval shunt for type I GSD also developed 
multiple filling defects in her enlarged liver. When the diseased 
liver was replaced at transplantation, all of the metabolic abnor-
malities of type I GSD were completely relieved. 123 It has been 
proved from the study of more than a half-dozen liver-based in-
born errors of metabolism that the phenotype of the trans-
planted organ permanently retains its original donor specific-
ity.I.12 
One other child developed a blood ammonia concentration of 
85 J.Lg/dl (normal, < 60 J.Lg/dl in that laboratory), but there were 
no symptoms of encephalopathy. This patient died almost 5 
years after portacaval shunt construction during an attempt at 
transcaval radiographic visualization of the portacaval anasto-
mosis. Except for the slightly elevated blood ammonia concen-
Fig 14.-The dramalic wrist and hand bone growth and mineralization in a palient 
with type I glycogen storage disease by 11'/2 months postoperalively. The bracket 
on the left index linger is 5 cm in length. (From Starzl et al.l9 Reproduced by per-
mission.) 
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tration, standard liver functions were normal. At autopsy the 
liver showed macroadenomatosis, very similar to that in the 
child who underwent liver transplantation. An autopsy finding 
that had not been suspected in life was advanced right ventric-
ular hypertrophy and dilatation. The smaller pulmonary arte-
ries and arterioles showed medial muscle hypertrophy,' medial 
and intimal fibrosis, scattered fibrinoid necrosis, and numerous 
plexiform lesions. Such cardiopulmonary complications have 
been documented in other patients with type I GSD and other 
liver diseases. 14:1 This complication did not have an obvious re-
lationship to the portacaval shunt. Themacroadenomatosis seen 
in these patients is very common in patients with type I GSD 
and was recently reported in seven of eight nonshunted patients, 
aged 3-28 years. 144 
The Present Status of Portal Diversion 
Portacaval shunt in the treatment of GSD has been sup-
planted by the continuous night feeding schedule advocated by 
Greene et al. l :1!I Portacaval shunt, if it has any role at all, is 
reserved for failures of this more conservative and liver-sparing 
approach. We have not performed a portacaval shunt for GSD 
since October 1976. 
FAMILIA L I I YPERCHOLESTEROLEMIA 
In March 1973, a 12-year-old girl with homozygous FH was 
treated with an end-to-side portacaval shunt; her serum choles-
terol concentration fell markedly.20 In patients with this disease, 
there is an absence or deficiency of cell membrane lipoprotein 
receptors H5 . 146 and thus no "switch-off' mechanism to control 
lipid (especially cholesterol) synthesis. 
By the summer of 1982, 12 patients with FH had been treated 
by us in this way. Eight of the patients were children, aged 2-
14 year-so The four adults were aged 21, 31, 37, and 52 years. All 
but two were homozygous for the FH abnormality. Low-density 
lipoprotein (LDLl receptors were determined by Goldstein and 
Brown 1-15 on cultured fibroblasts obtained from all patients and 
many of their close relatives. Nine of the len patients with ho-
mozygous disease were LDL-receptor negative and the other was 
LDL-receptor defective. Two of the patients had heterozygous 
disease. 
The portacaval shunts were constructed by anastomosing with 
fine continuous suture the cut end of the portal vein to an ellipt-
ical defect in the anterior or anterolateral wall of the supra-
renal inferior vena cava. Tributaries to the portal vein above the 
site of its transection were looked for and ligated. The anasto-
moses were made slightly larger than the natural diameter of 
the portal vein. Although hypercoagulability has been described 
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in FII,II, IlO anticoagulant!:; were given during or after opera-
tion. Thrombosis after portacaval shunt in children with portal 
hypertension has been so high that most pediatric surgeons pre-
fer to use the operation only in patients older than 8 or 10 years 
amI in those whose anastollloses can he made at least I ~fll in 
diallleter. I "'. Ilh Although the!:;e minimum conditions did !lot ob-
tain in the majority of our patients, there were no thromboses 
Hnd 110 de<1ths. 
Efl'el'i ()II Ser/ill/ LilJllis 
Total serum cholesterol concentrations fell significantly in 
every patient after portacaval shunt. 1:H When measured, LDL 
cholesterol levels were reduced commensurately. The total cho-
lesterol values declined 20';; -55.4'fi (average, PPKUDI~FI and this 
decline was maintained throughout the period of study. IIIlL 
cholesterol and triglyceride levels were variably effected. Ten-
dinocutaneous xanthomas regressed or disappeared in e\'ery pa-
lient {Fig 15). 
E.r/wri!'II(,1! (II' Others ill Treating FlI 
The consistency of the anticholesterolemic response was 
greater in OUI' patients than in patients treated by others. There 
are reports on a total of' 2fi additional patients, 13 of wholll were 
treated in Johannesburg. J.\!l 
In the 13 patients treated elsewhere than in Johannes-
burg,I:,1l :,7 s('rum cholesterol reductions of at least 30'fi wpre ob-
Fig 15.-The hands of a patienl wilh hyperlipidemia 2 weeks before (leN) and 16 
months after (righI' portacaval shunt. (From Starzf et al. 158 Reproduced by permis-
sion) 
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tained in ten, as well as regression of tendinocutaneous xantho-
mas to the same extent as originally reported by usK~nK ",H In two 
of the three exceptional patients, shunt thrombosis was 
proved, 1-,1. I C,;! and in one of these the cholesterol level fell by 
40',( after a later mesocaval shunt. 152 In the third patient, de-
scribed by Soutar, Myant, and Thompson,I:;a there was presump-
tive hut not definitive evidence of shunt occlusion. The choles-
terol level, after an early fall of 401Jc, returned several months 
later to near preoperative values. At the same time, initially 
elevated serum_~f~D~lagon levels, ~hich ar~ typically found with 
a patent shunt,' . I.. fell to baseline. 
The earlylfiO and subsequent 1-19 reports from ,Johannesburg 
have confirmed the value of portacaval shunt in FH hut have 
provided minimal incentive for expanded trials. Of LJ homozy-
gous patients with unstipulated membrane receptor status, one 
died 2 days postoperatively of a myocardial infarction. The re-
maining 12 had significant but often modest falls in serum tulal 
and LOL cholesterol levels, and the values later returned to or 
toward preoperative levels in three. Xanthomas regressed in 
eight patients, were stable in two, and increased in two. Almost 
all patients developed postoperative splenomegaly, a finding 
compatible with sluggisb or obstructed splanchnic venous drain-
age or, alternatively, with a manifestation of FII thal previollsly 
had not been appreciated. 149 
A full explanation for the indifferent results in the ,Johannes-
burg seri('s has not been forthcoming, but possihilities discussed 
elsewhere l21 include a high incidence of shunt thrombosis 01' in-
effective portal diversion, peculiarities of the FII endemic to that 
region of South Africa, or other less obvious factors. 
The invariable and long-lasting lipid lowering in our 12 pa-
t;ents was achieved without surgical morbidity. The physical de-
velopment of children \vho were normal hefill'e operation IInS 
proceeded, and the growth of those who were stunted hefine op-
eration has moved toward normal. As described ill an earlier 
section, emotional or intellectual deterioration secondary to the 
portal diversion has not occurred, although one child had an 
acute episode of encephalopathy which was Jllannged with diet. 
.1Ie('hul/isms or Lipid LOIl'l:'rillg 
The meclHlnisms causing lipid lowering ill patients with FII 
probably are qualitatively similar to those in experimental ani-
mals. discussed earlier in this monograph. 
Data rele\'ant to mechanisms in humans with FII an' also 
a\'ailable. Soutar et al.l:,1 found no change in LIJL synthesis and 
an actual rise in very-low-density lipoprotein ,VLDLJ synthesis 
in the patient discussed earlier whose shullt may have closed . 
Strikingly different conclusions were reached after metabolic 
studies in three of the 12 patients of our own series. In our pa-
tient 2. Bilheirner et al.'4 showed that cholesterol and LDL syn-
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thesis, which were inappropriately high before portacaval shunt, 
were reduced afterward by 62lk and 48lk, respectively. The frac-
tional catabolic rate, which was only a third of normal at the 
outset, as is typical for FlI, fell further after operation. Ginsberg 
et al. IIi 1 studied the heterozygous patient 6 in our series; that 
patient responded to portal diversion with major reductions in 
LDL as well as VLDL apoprotein-B synthesis, in VLDL triglyc-
eride synthesis, and in the already subnormal fractional cata-
bolic rate. 
The extraordinary degree to which cholesterol homeostasis 
was altered by portacaval shunt in the homozygous patient 4 in 
our own series and the heterozygous patient 6 has been de-
scribed by McNamara et al.;5 Exogenous cholesterol absorption 
was unchanged in both patients, and bile acid synthesis was 
halved. Whole body cholesterol synthesis was decreased by 68 Ck 
in patient 4 and by 41 (Ic in patient 6. The total body cholesterol 
mass 1112 years after portacaval shunt was reduced by R9C;~ in 
patient 4 and by 43(/' in patient 6. These data are compatible 
with the extraordinary diminution or disappearance of tendino-
cutaneous xanthomas (Fig 15) and with the hope that the lethal 
cardiovascular complications of FH can be slowed or forestalled 
by portacaval shunt. 
Effect orl Caniiol'ascliiar Disease 
The degree to which the cardiovascular complications of FH 
can be relieved or prevented by portal diversion has not been 
established. Reversal of aortic stenosis was seen in two of our 
patients, but regression of atheromas in the coronary arteries 
and aorta was not regularly achieved. 124 Small and Shipley 162 
have examined factors that could preclude the reversal of ath-
erosclerosis, and some of these, including secondary fibrosis, 
would not be corrected completelrl; by the resorption of intravas-
cular xanthomas. Farriaux et al. 6:1 have suggested that anatom-
ical stabilization of the vascular disease may be the best that 
can be achieved with a portacaval shunt, even in patients whose 
angina pectoris is relieyed~K bx~erience in several patients at our 
center and elsewhere l24. 1.).1. 15 has shown the value of aggres-
sive surgical correction of technically remedial cardiovascular 
lesions in combination with portal diversion. Of greater impor-
tance will be the implementation of aggressive therapy at a 
young age, before irreversible cardiovascular complications de-
velop. In patients with FH who are refractory to therapy \vith 
diet and medications, portacaval shunt may be the treatment of 
choice. Postoperatively, medications and diet should be tried 
again, since further declines in postshunt cholesterol levels have 
been seen using diet and medications which had previously been 
ineffecti ve. 
The staged combination of portacaval shunt and the ileal Ly-
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pass procedul'e of Buchwald et a\. 164 has been tested in three 
patients. The combination had an apparently additive ef-
fect!4!1. 156 even thou~h ileal bypass alone has little or no effect 
on homozygous FH. I .\ I n dogs, Guzman et a\. If;f> have noted an 
additive effect of portal diversion (by portacaval transposition) 
plus ileal resection. Efforts by US l66 to document a complemen-
tary effect of ileal resection and portacaval shunt in dogs failed 
to confirm tbe claims of Guzman et al.,165 and a subsequent re-
port by Rucker et al. 167 from the Minnesota study has shown 
that the additive effect originally reported by Guzman was not 
sustained. 
Limitatiolls of Portacaval Shunt 
Portacaval shunt, with or without supplementary treatment, 
is only pal\iative in patients with FH. The amelioration of the 
abnormal metabolic patterns of FH has derived from the coun-
tervailing and potentially dangerous hepatic abnormalities 
caused by portacaval shunt (see Fig 3). The palliation has been 
incomplete, since restoration of normal serum cholesterol values 
has not been achieved in any patient with homozygous disease. 
Because of the evidence of a central hepatic role in the regula-
tion of lipid metabolism,'6H-17I it is possible that the metabolic 
abnormalities of FH could be rectified by the ultimate' step of 
liver transplantation. 
PORTAL DIVERSION FOR (XI-ANTITRYPSIN DEFICIENCY 
In both GSD and FII, the generally adverse effects of portal 
diversion have been accepted as the price for improvement of 
even more serious metabolic perturbations. There is a possibility 
that a third inborn error, (XI-antitrypsin deficiency, may be 
added to th is list. I 72 
Patients with this disorder have a low level of plasma nl-an-
titrypsin (an a-globulin) and a high incidence of pulmonary com-
plications. 173 In 1969, Sharp et a1. 174 demonstrated a variable 
association of the aI-antitrypsin deficiency with liver disease, an 
observation that has had (lverwhelming confirmat.ion. 175. 176 It is 
now accepted that (Xl-antitrypsin deficiency is a common cause 
of chronic liver disease both in the pediatric and in the adult 
populfltions. 
The probable p,athogenesis of the liver disease has been re-
cently reviewed. 77 In essence, the basis for the liver injury may 
be the hepatic production of an abnormal {XI-antitrypsin which 
cannot be effectively transported out of the liver cells and which 
consequently becomes sequestered within the hepatocytes near 
the RER. Irritation by the entrapped glycoprotein has been pos-
tulated as the cause of the hepatic cirrhosis, portal hypertension, 
and hepatic failure that follow. The progressive and inexorable 
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course that this pathogenesis implies may have discouraged at-
te~pts to treat complications of the portal hypertension (such as 
varIceal hemorrhage) with portal-systemic shunts. In addition, 
the results with portal diversion have been poor.17R-180 Only So-
tos et al. 181 have reported encouraging results, and their obser-
vations were limited to two children. 
We have performed end-to-side portacaval shunt in three chil-
dren with the cirrhotic liver disease of lXI-antitrypsin defi-
· 182 
clency. The first two patients had major hemorrhages from 
esophageal varices. The third had ascites, but the principal rea-
son for operation was the hope of influencing the metabolism of 
the lXI-antitrypsin. 
Follow-up data of 3 112, 5, and nearly 7 years are available. 182 
Standard Jiver function tests have not changed greatly since the 
portacaval shunt, ·although the plasma ammonia levels have 
been :Ievated in both patients in whom measurement was sys-
tematIcally made. None of the three patients have had symp-
toms of encephalopathy, although patient 2 had mental slowness 
for the first 2 years after operation. 
· The possibility that the Jiver damage of lXI-antitrypsin defi-
ciency can be slowed by portacaval shunt has been emphasized 
by ~he st~l~igizatjon in all three patients of a previously deterio-
ratmg clinIcal state. However, the most objective evidence that 
the natural history of the disease was favorably altered by por-
taca~al shunt ~ame from the histopathologic studies of biopsy 
specImens obtamed operatively and postoperatively in patients 
2 and 3. IS:.! In patient 2, a biopsy specimen obtained 9 months 
after the portal diversion showed a reduced number of hepato-
cytes containing lX I-antitrypsin globules-28.5%, compared to 
38.2lit at the time the portacaval shunt was constructed. The 
hepatocytes were 22'fr smaller, and the amount of RER in their 
cytoplasm was greatly reduced. 
In patient 3 the percentage of hepatocytes containing (ll-anti-
trypsin globules was 44.57£' at the time of operation and 48.2% 
and 38.7 Ck at 7 and 13 months, respectively, after portacaval 
shunt. The hepatocytes were 157c and 201Jc smaller at these 
postoperative follow-up times. The percentage of hepatocytes 
containing tll-antitrypsin globules was reduced to 20.4'fr in the 
biopsy specimen obtained 35 months postoperatively. The hepa-
tocy~es remained 20 l k smaller than in the preoperative biopsy 
speCImen, and the amount of both RER and SER in their cyto-
plasm was reduced. The severity of the macronodular cirrhosis 
was unaltered. 
· We assume that the portacaval shunt diminished the synthe-
SIS of the abnormal ul-antitrypsin, presumably by altering the 
function of the RER and its ribosomes (see earlier section on 
hepatic function after construction of Eck's fistula) without com-
mensurately reducing the transport of this glycoprotein. 172, IH2 
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With a better equilibrium between the production and transport 
of the u-globulin, it is possible that its intracellular accumula-
tion has been slowed or probably even reversed. 
PORTAL-SYSTEMIC SHUNT FOR COMPLICATIONS 
OF PORTAL HYPERTENSION 
We have emphasized the morphological and metabolic 
changes caused by portal diversion and the explanations for 
these wide-ranging effects. The inescapable conclusion from all 
of the work on this subject in the last decade is that portal-sys-
temic diveTsionis so inherently harmful to the liver that it 
should be considered only for life-threatening disease conditions 
or complications. Exploitation of portal diversion for its increas-
ingly well-understood metabolic effects, as described in the pre-
ceding section, has been a recent development and one that is 
still in evolution. In contrast, there is little new of a conceptual 
nature that can be written about the use of portal-systemic 
shunting for mechanical and hemodynamic objectives, except for 
the contributions of W. Dean Warren and his associates. 
As mentioned at the outset, Eck envisioned the use of porta-
caval shunt for the treatment of hepato~enic ascites.:1 In their 
historical treatise, Donovan and Covey I :1 described how other 
surgeons interested in the procedure realized that it also might 
be a way to control hemorrhage from esophageal varices. 
Vidal lA4 was probably the first (June 1903) to construct a porta-
caval shunt successfully. His patient, a 34-year-old alcoholic 
man, had ascites and a 7-week history of recurrent variceal 
hemorrhages. He survived more than 3 months after operation. 
Both of the principal complications of portal hypertension, as-
cites and hemorrhage, have been extensively treated hy a vari-
ety of portal-systemic shunts since Whipple lR5 and Blakemore 
and Lord l86 ushered in the modern era of this field not quite 40 
years ago. Although portal diversion often dries up ascites, its 
use for this purpose has been all but abandoned because of the 
mortality and morbidity (especially encephalopathy) of the pro-
cedures, because better diuretics have made ascites easier to 
control, and because the safer peritoneal-venous (LeVeen-typel 
shunts can be used if nonoperative care is unsuccessful. Ifl7 
The boom in portal-systemic shunts to control variceal bleed-
ing has lasted longer, but such procedures are heing rec-
ommended far less frequently today than they were a few years 
ago. The downward trend undoubtedly will continue, for sevenll 
reasons. The developments in hepatotrophic physiology summa-
rized in this monograph have shown how destructive to the nor-
mal liver portal diversion can be. The incongruity of deliherately 
imposing such an insult on an organ already abnormal and la-
boring under the handicap of intrinsic parenchymal disease has 
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not escaped the attentiun uf thoughtful clinicians. Furthermore, 
the results of randomized clinical trials during the last 20 years, 
in patients with or without previous variceal hemorrhage, have 
not demonstrated u statistically significant increase in sUI"\,i\'ul 
after any kind of portal-s~stegllic shunt compared to that achiev-
able without operation.' >I. !!II The decrease in morta Ii ty from 
gastrointestinal hemorrhage after shunting has been canceled 
by perioperative deaths and,or by a higher suhsequent death 
rate from hepatic failure. Consequently, alternative methods to 
control vuriceal bleeding without changing the preexisting he-
patic blood flow patterns have been viewed with increasing in-
terest. The Illost promising techniques are sclerotherapy of the 
varices'!';' 1!17 und transhepatic embolism of the left gastric Icor-
onary) vein.'!JH. I!I!' 
The growing nihilism ahout portal diversion in patients with 
advanced hepatic disease will be justified to the extent that liver 
transplantation becomes an option in future years. An existing 
shunt, or for that matter, any kind of previous upper abdominal 
operation, is an extremely negative factor in a patient being 
considered for hl'patic transplantation, H:I and may preclude such 
transplantation. 
In the meantimc, a limited number of patients will he bona-
fide candidates for portal-systemic shunts. Available shunting 
techniques are illustrated in Figures 16 and 17. The literature 
on the various shunt operations is so voluminous and so fre-
quently contradictory that no efTort is made to review it here. 
The interested reader can quickly obtain a relatively complete 
idea of what has been written by perusing anyone of three re-
cent reviews.:!oo :!O:l 
POHTAI. Fl.ow STlllllES IN SIIUNT PLANNIN(; 
A logical decision about the type of shunt to be used cannot 
be made without ascel·taining whether there is still perfusion of 
the liver by portal blood (hepatopetal flow). Although there is no 
completely accurate technique to obtain this information. rough 
estimates of residual portal /low can he made with latl' phase 
venograms after selective celiac or superior mesentl'ric arteri-
ography,:.!Il:I. :!(I.j or by direct dye injection into the splanchnic ve-
nous ~1K~tem using splenoportEFgraph~I_O";D transhepatic portog-
raphy,-'''' or umhilical venographyK~"f A more quantitative 
estimate may IH'cornl' a practical objective in the future. Hik-
kers, Miller, and ChlDislian:!Eg~ have described a radiocolloid ll'ch-
nique for quantifying the fraction of superior mesenteric venous 
blood that perfuses the hepatic sinusoids. 
The concept of using this kind of hemodynamic information 
for preoperative assessment can be traced back through the lit-
erature for several decades, particularly in the publications of 
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Fig 16.-Kinds of portal-systemic shunts. A, end~to-side portacaval shunt B, 
variety of side·to·side shunts. C, seleclive portal-systemic shunts 
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Fig 17.-End-lo-side portacaval shunt, combined with arterialization of the lied-off 
cenlral portal vein. 
Womack and his associates,:109.21O but its general acceptance 
came from the brilliant studies of Warren, Zeppa, and Fomon,211 
published in 1967. The Warren-Zeppa-Fomon article was the 
first step toward the increasingly accepted objective212 of decom-
pressing esophagogastric varices without paying the penalty of 
hepatic portal flow deprivation. 
COMPLETELY DIVEHTlNG SHUNTS 
End-la-Side Porlacaval Shunt 
The standard shunt against which all other shunts must be 
compared is the end-to-side portacaval shunt (see Fig 16,AI. 
With this operation, complete portal diversion is achieved 
quickly, easily, and with very little blood loss; the portal diver-
sion is the same as that achieved with a well-constructed Eck's 
fistula in animals. Because pressure in the splanchnic venous 
system is reduced, hemorrhage from esophageal varices is prac-
tically eliminated. This is the sole benefit from the operation, 
with the possible exception of relief of ascites. 
The other effects of the operation are predictably adverse. The 
loss of liver perfusion with hepatopetal portal venous blood, in 
those patients still possessing such a flow, immediately puts the 
patient at potential risk of the portoprival <Eck fistula) syn-
drome. Undoubtedly, the resulting encephalopathy is mainly a 
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reflection of diminished hepatic function. In addition, Price,l':J 
Harrison/14 and Rikkers21 and their associates have reportf'd 
that the low venous pressure in the splanchnic bed after porta-
caval shunt can contribute to increased absorption of metabo~ 
lites, intestinal toxins, and probably ammonia. This "Iow-pres-
sure" absorption factor was recognized b~ Warren et al. more 
than 15 years ago,211 as well as recently, 12 as a possible ancil-
lary mechanism for the high incidence of encephalopathy seen 
after construction of completely diverting end-to-side or side-to-
side portacaval shunts. 
Side-la-Side Portal-Systemic Shunls 
The side-to-side shunts are constructed with portacaval, cavo-
mesenteric (Marion-Clatworthy), mesocaval, or conventional 
splenorenal anastomoses (see Fig 16,B). These shunts were once 
thought to yield different results than the end-to-side shunts; it 
was assumed they did not completely eliminate portal perfusion. 
However, all effective side-to-side shunts are merely variants of 
a common theme, as shown in Figure 16,B: all of the blood re-
turning from the distal splanchnic bed, as well as a variable 
amount from the sinusoids of the liver itself, can pass into the 
systemic venous circulation. The claim that hepatopetal portal 
blood flow is partly retained after such side-to-side procedures 
has been shown to be untrue if the shunts are of adequate 
. 201 208 216-224 Th th I' t' f h t' f'l . size. .. us, e comp lca IOns 0 epa IC al ure, 10-
cluding encephalopathy, after the various side-to-side shunts in 
controlled series have been as common as after end-to-side por-
tacaval shunts. 19l , 221, 225 The mesocaval H-graft operation of 
Drapanas226 is no exception, and in addition, the prosthesis used 
in this procedure has had an exorbitant rate of late thrombo-
sis.227 
SELECTIVE PORTAL-SYSTEMIC SHUNTS 
The direct and indirect messages of this monograph have con-
cerned the special qualities of portal venous blood in the main-
tenance of liver health. Extrahepatic diversion of this blood with 
a portal-systemic anastomosis imposes such a drastic handicap 
on the liver that this kind of procedure should be used rarely 
and only for overwhelming reasons. Furthermore, total portal 
diversion is a desirable feature of a shunting procedure only if 
the objective is the "metabolic engineering" described in an ear-
lier section. 
If the objective is to prevent recurrent hemorrhage from 
esophageal varices in a patient who still has significant hepato-
petal portal venous flow, the decision to construct a selective 
portal-systemic shunt should be beyond rational criticism. The 
selective diversion procedures that have been used clinically in-
clude the original Warren-Zeppa-Fomon distal splenorenal 
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shunt (see Fig 16,C, left side); an uncommonly performed modi-
fication also described by Warren et al.,212 whereby the distal 
splenic vein is anastomosed to the inferior vena cava (see Fig 
16,C, middlel; and the direct anastomosis of the coronary vein 
(left gastric) to the inferior vena cava, described by Inokuchi et 
al. 22H (see Fig 16,C, right sidel. 
The problems with using selective shunts in patients with re-
sidual hepatopetal flow have been practical rather than concep-
tual. Experience with the Warren shunt has shown this shunt 
to be technically more sophisticated and difficult to construct 
than the conventional portacaval shunt. It cannot be easily con-
structed under the urgent circumstances of acute variceal hem-
orrhage, it is probably contraindicated in the presence of severe 
ascites, and it requires anatomically specific conditions that 
should be defined with preoperative angiography.212 Yet ifit can 
be accomplished, the Warren procedure effectively decompresses 
esophageal varices while maintaining portal venous flow. As 
would be predicted, it is associated with a demonstrably better 
preservation of hepatic biosynthetic processes, such as urea pro-
duction,229 than is portacaval shunt and it carries a far lower 
incidence of hepatic encephalopathy.20o. 215. 222-224. 2:10. 231 The 
stakes are so high for patients who meet the candidacy criteria 
for a distal splenorenal shunt that it is difficult to justify con-
signing them by random lot to a conventional totally diverting 
shunt group for the purposes of a clinical study. The probabil-
ity that the selective shunts are superior is not a null hypoth-
esis. 
Nevertheless, randomized trials comparing distal splenorenal 
versus totally diverting shunts have not revealed a striking 
divergence in the life survival curves. 2IlO. 222-224. 2:111. 2:11 If this 
trend continues, a better quality of life (as opposed to mere 
survival) may prove to be the only justification for the selective 
shunts. 
If selective shunt procedures fail to provide a better life sur-
vival than totally diverting portacaval shunts, the most funda-
mental reason undoubtedly will be that the patients under 
treatment have progressive hepatic diseases of such an immut-
able course that the effect of therapeutic intervention cannot be 
measured accurately against the background "noise" (roar might 
be a better word) of the disease itself. However, other factors 
might playa minor role in masking the superiority of selective 
shunts, including a higher perioperative mortality while sur-
geons learn how to carry out the Warren procedure. 
Finally, in most patients, the preserved residual hepatopetal 
portal flow is gradually "stolen" from the liver as blood from the 
high-pressure mesenteric bed is recruited into the low-pressure 
area drained by the distal s~lenorenal shunt.2n O1~-OP4 As dem-
onstrated by Maillard et aI., 32 the distal splenorenal shunt car-
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ries a high flow that is driven by the splenic arterial input. Un-
doubtedly this protects the splenorenal anastomosis from 
thrombosis, but it also gives the selective shunt circuit some of 
the features of a thirsty and larcenous arteriovenous fistula. 
However, the c?nsequent loss of porta.l .. he~atic perfusion is so 
gradual after dIstal splenorenal shunt222. 2 ~ that there is time 
(months or years) for compensatory physiologic adjustments, in-
cluding augmentation of the hepatic arterial input. If a high in-
testinal venous pressure is maintained throughout this time, the 
absorption of ammonia and other so-called cerebral toxins 
should be lower than after c0n:trletely diverting portacaval 
shunt (see earlier discussionl. 215. 23 
TilE CONCEPT OF PORTAL ARTERIALIZATION 
The possibility of replacing the lost portal flow with arterial 
blood, after a completely diverting portacaval anastomosis, has 
been examined in many experimental laboratories. Clinical 
trials with such procedures have been under way in one Ameri-
can center236 and one European center.237 Theoretically, such 
operations could have a minor beneficial effect. The hepato-
trophic constituents that are diverted around the liver become 
available in diluted form via the arterial system and would be 
brought to the liver in direct relation to the quantity of hepatic 
flow. As discussed earlier, this is the explanation for the benefits 
of both the Child portacaval transposition and the portal arter-
ialization procedures. 
Nevertheless, it is important to emphasize the limitations of 
any benefit from such flow augmentation procedures. Marchioro 
et al. 39 showed that the atrophic changes in liver segments de-
prived of splanchnic venous inflow could not be prevented by 
arterializing the liver tissue, even though the arterialization 
procedures increased the flow to several times normal. Consis-
tent with these observations were those of Pector et al.,RO. RI who 
showed that the depressed activity of the mixed-function oxidase 
system could not be restored after portacaval shunt by portaca-
val transposition or by rearterialization of the portal vein 
stump. 
Portal vein arterialization in experimental animals has had a 
specific risk. Cohn and Herrod238 report.ed venous sclerosis as a 
consequence of the high pressure and flow. Efforts to prevent 
overperfusion by using very small inflow vessels or by damping 
flow with deliberate stenosis predictably increase the risk of 
thrombosis. 
It is our opinion that portal arterialization procedures will 
have no effect whatever on either the morbidity or mortality af-
ter a completely diverting portal-systemic diversion in patients 
with portal hypertension. 
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SUMMARY 
In all species so far studied, including man, portacaval shunt 
causes the same changes in liver morphology, including hepato-
cyte atrophy, fatty infiltration, deglycogenation, depletion and 
disorganization of the rough endoplasmic reticulum (RERl and 
its lining polyribosomes, and variable but less specific damage 
to other organelles. Many, perhaps all, biosynthetic processes 
are quickly depressed, largely secondary to the selective damage 
to the RER, which is the "factory" of the cell. 
These structural and metabolic changes in the liver after por-
tal diversion are caused by the diversion around the liver of the 
hepatotrophic substances in portal venous blood, of which endog-
enous insulin is the most important, In experimental animals, 
the injury of Eck's fistula can be prevented by infusing insulin 
into the tied-off hilar portal vein. 
The subtle but far-reaching changes in hepatic function after 
portal diversion have made it possible to use this procedure in 
palliating three inborn errors of metabolism: glycogen storage 
disease, familial hypercholesterolemia, and ai-antitrypsin defi-
ciency. In these three diseases, the abnormalities caused by por-
tal diversion have counteracted abnormalities in the patients 
that were caused by the inborn errors. In these diseases, amelio-
ration of the inborn errors depends on the completeness of the 
portal diversion. 
In contrast, total portal diversion to treat complications of por-
tal hypertension is undesirable and always will degrade hepatic 
function if a significant amount of hepatopetal portal venous 
blood is taken from the liver. When total portal diversion is 
achieved (and this is to be expected after all conventional 
shunts), the incidence of hepatic failure and hepatic encephalop-
athy is increased. If portal diversion must be done for the control 
of variceal hemorrhage, a selective procedure such as the War-
ren procedure is theoretically superior to the completely divert-
ing shunt. In practice, better patient survival has not been 
achieved after selective shunts than after conventional shunts, 
but the incidence of hepatic encephalopathy has been less. 
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COMMENT 
"Impressive" is probably the word that most effectively de-
scribes this monograph by Dr. Starzl. The extensive bibliogra-
phy weaves together a series of clinical observations and animal 
studies into a fabric whose design reflects the role of insulin as 
the hepatotrophic factor in maintaining normal liver function. 
When diverted by portal systemic shunting, insulin fails to 
reach the liver in sufficient quantity to prevent deterioration. 
For years Dr. Starzl has been one of the most imaginative, 
innovative, and energetic investigators in academic surgery. In 
this monograph, he and his co-authors describe some of their 
ingenious and difficult experiments, experiments designed to 
clarify the role of pancreatic internal secretion in the portal vein 
and the support of hepatocellular growth and function. Studies 
by Marchioro when he was working in Dr. Starzl's laboratory I 
were carried out on an animal preparation that has been de-
scribed as a split (or partial) transposition. The procedure cre-
ated two liver segments, one of which was perfused with portal 
blood while the other was supplied with blood from the inferior 
vena cava; these and confirmatory studies by Price et al.,2 Lee 
et al.,3 and Chandler et al. 4 indicated that hypertrophy occurred 
in the liver tissue perfused with portal blood but atrophy oc-
curred in the liver segment provided with systemic venous in-
flow. These studies unequivocally supported the induction that 
portal blood was an important factor in the maintenance of he-
patic function. No one who accepted the basic concept of the 
"wisdom of the body" could doubt this or fail to welcome the 
scientific confirmation of intuition. Later studies by Starzl and 
co-workers5 . fi on the effect of insulin versus glucagon and other 
substances on hepatocyte proliferation emphasized the impor-
tant role of insulin in general hepatic function as well as in car-
bohydrate metabolism, although the two are so intertwined that 
distinction is difficult. Thus, one cannot escape the conclusion 
that insulin is an important factor, although Starzl does suggest 
that there is probably multifactorial control of hepatocyte integ-
rity. If one considers the rich substrate of "building blocks" in 
portal venous blood for carbohydrate, protein, and fat metabo-
lism, and the many endocrine factors involved, it is obvious-
ly difficult to accept the existence of a single "hepatotrophic 
fador." 
The search for a hepatotrophic factor has been a symbolic 
Grail to any number of investigators in the area of regeneration 
of the liver following major resection. This remarkable phenom-
enon begins immediately after removal of 50o/c-60sr of the liver 
with explosive DNA activity and proliferation of mitotic cell di-
vision, and full restoration of hepatic mass occurs before the pro-
cess ceases as abruptly as it began. The single hepatotrophic fac-
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tor aFter hepatic resec~ion has been as elusive as a simplistic 
solutIOn to the extensive and varied metabolic abnormalities 
~hich may occur, unpredictably, after portal-systemic shunting 
In man. 
A major section ?f ptar~yDs monograph is tenuously but impor-
tantly related t? hIS. theSIS .on the hepatotrophic factor in portal 
blood. He descnbes In detail the effects of portal diversion on a 
series of inborn errors of metabolism, an area in which he has 
been a pioneer. This section of the monograph is concerned with 
the apparent benefits observed after end-to-side portacaval 
shunt in children with glycogen storage disease (GSD), familial 
hypercholesterolemia (FH), and ai-antitrypsin deficiency. The 
effects of the operation were undeniable. Nevertheless, there re-
mains an unanswered question about these patients, in whom 
portal diversion was carried out for rare metabolic disorders. 
Why was there little evidence of portal-systemic encephalopathy 
(one suggestive case) in these patients, and only equivocal evi-
dence of hepatic deterioration? 
At this point, we might review some of the more significant 
observations on liver and general metabolic function concerned 
with diversion of portal blood around the liver. Starzl has em-
phasized that the single observation to be garnered from Eck's7 
limited experiments is that in one animal, the operation was 
compatible with life. Like many other important studies the 
first significant observations were made in the laborato;y of 
Pavlov, where he and his associates first described the phenom-
enon of "meat intoxication" in laboratory animals in whom Eck's 
fistula had been constructed.s In the following decades a number 
of studies carried out in Europe and the United States suggested 
that many factors could be causative, without, however, sub-
stantiating any of them. Van Caulaert and colleagues9 and Ga-
buzda and colleagues lO suggested that hyperammonemia might 
be related to the disorders in cerebral metabolism but thought 
that hyperammonemia was more likely due to hepatocellular 
dysfunction in the cirrhotic patient than to the portaprival syn-
drome associated with diversion of portal blood. 
During the decade following World War II, the era of portal-
systemic shunting in man for protection against hemorrhage 
from esophagogastric varices began and developed raridly, 
spurred on by the clinical work of Whipple II Blakemore I Lin-
t 13 R I 14 M 0 15 ' , on, ousse ot, c ermott, and many others. Although 
well over 100 shunting procedures were carried out over a 10-
year period, there was no report or even a suggestion that the 
shunts were related in any way to hepatic dysfunction, enceph-
alopathy, coma, or death; in general, these adverse effects were 
t~ought to be due to a progression of the basic hepatocellular 
disease. The concept of the portaprival syndrome had not yet 
been articulated. 
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In 1953, at a time when it was hoped that the extension of 
radical surgery might improve the cure rate of cancer, we car-
ried out pancreaticoduodenectomies with resection of the portal 
vein and establishment of an anastomosis between the superior 
mesenteric vein and the inferior vena cava. IS It was not long 
before the peculiar constellation of intermittent neurologic dis-
orders that appeared after the initial operation was recognized 
and thought to be related to the shunt, and probably similar to 
those found by Pavlov many years before. Clinical and metabolic 
studies demonstrated that in fact the neurologic disorder was 
related to the ingestion of nitrogenous material (urea and am-
monium salts), could be prevented by the use of some of the 
early intestinal antibiotics, and was associated temporally with 
rapidly changing ammonia levels in the peripheral blood. 16 
Shortly after this, Hubbard, replicating this operation for cancer 
of the head of the pancreas, recognized the same phenomenon 
(referred to by Starzl as the McDermott-Hubbard artifactl. This 
resulted in a confirmatory publication from Hubbard.17 Thus, 
the stage was set for extensive laboratory and clinical investi-
gations on the effects of portal-systemic shunting. In the labo-
ratory, a series of investigations on dogs with Eck's fistula con-
firmed the existence of the "meat intoxication" syndrome. 18 
Following these initial clinical and laboratory observations, a 
review of portal-systemic shunts19 confirmed the existence of the 
syndrome of portal-systemic encephalopathy, as it was later 
named by Sherlock.:lO 
A simplistic explanation would be that the ingestion of nitro-
genous material with subsequent digestion and eventual forma-
tion of ammonia, amines, and amides by the action of colonic 
bacteria would result in toxic encephalopathy if these sub-
stances bypassed the interposed detoxification mechanisms in 
the liver. The complexities and interreactions of human metab-
olism, however, rarely permit simplistic explanations, and it 
soon became clear that if the normal liver was deprived of portal 
blood, a series of adverse effects on hepatocellular function took 
place, (such as has been so beautifully outlined by Dr. Starzl in 
his review), in addition to the reversible syndrome of portal-sys-
temic encephalopathy related to introduction of nitrogenous ma-
terials into the intestines. At this point, no hepatotrophic factors 
had been identified, although it was clear that the portal blood, 
compared to systemic, arterial, or venous blood, was rich in sub-
strate, and that deprivation of these substances might adversely 
aflect the liver. 
As one moves from the clinic to the laboratory and back again, 
it becomes apparent that it is difficult to replicate in the labo-
ratory some of the problems and diseases one finds in man, and, 
conversely, that one cannot morally and ethically carry out ef-
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fective and controlled studies in man when adverse effects can 
be anticipated. 
Thus, recognition of the adverse effects of constructing a por-
tal-systemic shunt in an organism with a normal liver prevented 
a:ny furt~er studies in m~nI a~d in the laboratory it 'fas impos-
SIble to Induce changes Identical to those seen in cirrhosis in 
man. 
Chance observations in man do appear, and even an anecdotal 
~eference may be relevant. For example, Starzl suggested that, 
In the course of pancreaticoduodenectomy with resection of the 
pot·tal vein, the reports of ourselves 16 and Hubbard 17 were in-
validated because resection of a major portion of the pancreas 
would itself deprive the organism of insulin, a purported major 
hepatotrophic factor. This may be a valid comment, but it would 
have been impossible to repeat such an experiment in man were 
it not for a chance observation that is worth reporting in some 
detail. Linton, one of the pioneers in shunt surgery, carried out 
an exploratory laparotomy on a woman in her mid-30s who had 
recently developed esophagogastric varices with repeated mas-
sive hemorrhages; at operation and after dissection of the portal 
vein, he found that the lumen was completely occluded by a 
rather loosely attached clot, which he was able to remove com-
pletely. Having embarked on the procedure with the intention 
of carrying out a protective shunt, it was not surprising at that 
time, and with the limitations of knowledge .·egarding the por-
taprival syndrome, that he carried on with the planned proce-
dure of an end-to-side portacaval shunt. After operation the 
young woman had a course identical to that described for pan-
creaticoduodenectomy patients, developed a progressive deterio-
ration in hepatic function (although the liver was entirely nor-
mal at the time of operation), was completely intolerant of 
protein, and eventually died of a complex series of events which 
do not require detailed reporting for the purposes of this discus-
sion. Thus, chance confirmed that the changes originally re-
ported by US l6 would occur in a human being with a normal liver 
in whom a portal-systemic shunt with complete diversion was 
constructed, even when the pancreas was left intact. 
Continued observation and studies from many sources seemed 
to present more paradoxes than solutions. Why did this syn-
drome, related to protein intolerance in the presence of diversion 
of portal flow, occur universally in normal laboratory animals 
but in only roughly PM~ of patients in whom the shunt was con-
structed for portal hypertension secondary to cirrhosis? Why did 
patients with periportal fibrosis from schistosomiasis and in 
whom diverting shunts were constructed have almost uniformly 
disastrous results, compared with cirrhotics, even when their 
liver function was completely normal? On the other hand, why 
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did children with an extrahepatic block and in whom spleno-
re.nal or mesocaval shunts were constructed appear to do well 
without these particular metabolic problems (although 
Voorhees:'!! has raised the question that untoward results may 
occur later in life)? Out of these paradoxes, and with the results 
of further experimental studies, the concept began to evolve that 
deprivation of flow to the liver was as important in the disor-
dered metabolic state as the effects secondary to the shunting of 
toxic metabolites around the protective mechanisms in the liver. 
The simplest paradox relating to the extrahepatic portal bed 
blocks seemed to be answered by neither the flow theory nor the 
newly developing hepatotrophic concept, since in these patients 
sinusoidal pressure was normal, collateralization had developed 
in the gastrohepatic ligaments, and flow was maintained 
through the hepatic parenchyma, despite the protective de-
compression provided by shunt. This clearly differed from the 
effects of an intrahepatic presinusoidal block, as in schistosomi-
asis, where the obstruction exists in the terminal branches of 
the portal circulation and collateralization around the block can-
not occur. 
Why, then, did so many patients with cirrhosis of the liver and 
other disorders associated with a portal bed block or an outflow 
block from the liver do remarkably well despite the construction 
o~ an end-to-side portacaval shunt? Without minimizing the se-
riOUS problems of hepatocellular dysfunction and recurrent en-
cephalopathy that occur unpredictably in these patients, be-
tween 50(k and 70fJf; will have a stable and satisfactory course 
for extended periods of time; absolute purity in clinical studies 
!s almost impossible, particularly in this patient group, which 
Includes alcoholics, so prone to recidivism. Any tentative an-
swers are further clouded by the known inexorable progression 
of posthepatitic cirrhosis and the innumerable other problems 
related to the disease but not necessarily to the shunt. 
Although Starzl emphasizes the role of hepatotrophic factors 
and deemphasizes the importance of flow, the observations of 
Child et al. 22 in 1953 are inescapable in that portacaval trans-
position did protect against the atrophy associated with shunt-
ing. Regeneration following resection proceeded well in these 
animals, in contrast to the Eck fistula dogs. Studies have been 
carried out on similar transposition preparations in our own lab-
oratory.23 In brief summary, one might say that the animals 
with portacaval transposition were strikingly different from the 
animals with Eck's fistula and remarkably like normal animals 
under the same laboratory conditions, although there were rel-
atively minor disorders in a number of biochemical, metabolic, 
and microscopic parameters. Certainly the animals with porta-
caval transposition did not show the progressive liver atrophy, 
malnutrition, deterioration of liver function, recurrent encepha-
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lopathy, protein intolerance, and death which made up the char-
acteristic course of dogs wi~h ~ckDs fistula. Thus, while portal 
flow may be and probably IS Ideal for the maximum mainte-
nance of the mammalian liver, it is quite clear that in the labo-
rat~ry at least, maintenance of systemic venous flow does protect 
~galnst most of the adverse effects of portal-systemic shunting 
In the normal m~mmalK rlti~ately we may be able to identify 
the group of patients who Will show the portaprival state and 
recurrent encephalopathy after portal diversion and thus ex-
cl.ude from consideration for portal-system shunting those indi-
vKlduals~ho would predictably dQ _pDorly. There.areother pa-
tIents, however. who, for whatever hemodynamic or metabolic 
reasons, continue to do well after portal diversion and could be 
offered the protection of portal decompression. The selective 
shunt described by Warren and his colleagues24 .26 may well be 
an improvement on previous types of total shunts but also has 
some recognized and some potential problems. 
This is not the place for an extended clinical discussion or 
analysis of pharmacologic. radiologic, or endoscopic methods of 
control of bleeding varices. but at the moment, none of these 
seems to provide the ideal solution we have all been seeking. To 
date, n:ither ~omplex experim~ntal preparations, nor sophisti-
cated bIOchemical and metabolic techniques, nor the introduc-
tion or reintroduction of a variety of clinical therapeutic ap-
proaches have yet led to a solution which is simple, obvious, and 
correct. 
WILLIAM V. McDERMOTT, JR., M.D. 
DAVID W. & DAVID CHEEVER PROFESSOR OF SURGERY 
HARVARD MEDICAL SCHOOL 
BOSTON, MASSACHUSETTS 
REFERENCES 
1. Marchioro T.L., Porter KA., Brown B.I., et al.: The errect of partial porta-
caval transposition on the canine liver. Surgery 61:723-732, 1967. 
2. Price J.B. Jr., Voorhees A.B. Jr., Britton R.C.: The role of portal blood in 
regeneration and function of completely revascularized partial hepatic uu-
tografts. Surgery 62:195-203, 1967. 
3. Lee S., Keiter J .E., Rosen H., et a!.: Influence of blood supply on regenera-
tion of liver transplants. Surg. Forum 20:369-371, 1969. 
4. Chandler .J.G., Lee S., Krubel R., et a!.: The roles of inter-liver competition 
and portal blood in regeneration of auxiliary liver trallsplant~K Sur/? Forum 
22:341-343. 1971. 
5. Starzl T.E., Porter K.A., Putnam C. W.: intraportal insulin protects from the 
liver injury of portacaval shunt in dogs. Lallcet 2:1241-1242,1975. 
6. Starzl T.E., Porter K.A., Watanabe K, et al.: The effects of insulin, glucagon 
and insulin glucagon infusions upon liver morphology and cell division aller 
complete portacaval shunt in dogs. Lancet 1:821-825, 1976. 
7. Eck N.V.: K voprosu 0 pcrevyazkie vorotnois veni: PredvaritP(noye Hooh-
751 
schjenye. Vuel/. Med. J. 130:1-2, 1877. (Ligature of the portal vein. trans. 
Child C.G. III: Surg. GYllecol. Obslet. 96:375-376, 1953.> 
B. Hahn M .. Massen 0., Nencki M., et al.: Die Eck'sche Fistel zwischen der 
unteren Hohlvene und der Pfortader und ihre Folgen fijr den Organismus. 
Arch. Exp. Pathol. Pharmakal. 32:161-210, 1893. 
9. Van Caulaert C., Deviller C., Halff M.: Troubles provoques par I'ingestion 
de sels ammoniacaux chez I'homme attient de cirrhose de Laennec. Compt. 
Rend. Soc. Bioi. 111:739,1932. 
10. Gabuzda G.J. Jr .• Phillips G.B., Davidson C.S.: Reversible toxic manifesta-
tions in patients with cirrhosis of liver given cation-exchange resins. N. 
EI/gl. J. Mcd. 246:124-130.1952. 
11. Whipple A.O.: The problem of portal hypertension in I'elation to the hepa-
tosplenopathies. Ann. Surg. 122:449-475, 1945. 
12. Blakemore A.H.: Portacaval anastomosis: A report of fourteen cases. Bull. 
NY Acad. Med. 22:254-264, 1946. 
13. Linton R.R.: Selection of patients for portacaval shunts with summary of 
results in 61 cases. Ann. Surg. 134:433-443, 1951. 
14. Housselot L.M.: Combined (one-stagel splenectomy and portacaval shunts in 
portal hypertension. JAMA 140:2B2-285, 1949. 
15. McDermott \V.V .• Jr.: A one-stage pancreatoduodenectomy with resection of 
the portal vein for carcinoma of the pancreas. Ann. Surg. 136:1012-1018, 
1952. 
16. McDermott W.V. ,Jr., Adams RD.: Episodic stupor associated with an Eck 
fistula in the human with particular reference to the metabolism of ammo-
nia. J. Clin. lrll'esl. 33:1-8, 1954. 
17. Hubbard T.R Jr.: Carcinoma of the head of the pancreas: Resection of the 
portal vein and portacaval shunl. Ann. Surg. 147:935-944. 1958. 
18. Riddell A.G .• Kopple P.N., McDermott W.V. Jr.: The etiology of "meat intox-
ication" in the Eck fistula dog. Surgery 36:675-684, 1954. 
19. McDermott WV. Jr., Adams RD., Riddell A.G.: Ammonia metabolism in 
man. Ann. SUr!! 140:539-556, 1954. 
20. Sherlock S., Summerskill W.G .. White L.P., et al.: Portal-systemic encepha-
lopathy: Neurological complications of liver disease. Lallcel 2:454-457,1954. 
21. Voorhees A.B. Jr .• Chaitman E., Schneider S., et al.: P-S (portal-systemic, 
encephalopathy in the non-cirrhotic patient. Arch. Surg. 107:659-662, 1973. 
22. Child C.G., Barr D .• Holswade G.R., et al.: Liver regeneration following por-
tacaval transposition in dogs. Ann. Surg. 138:600-608. 1953. 
23. Ono H .. Kokima Y., Ackroyd F.W., et al.: Long-term results in portarenal 
transposition in dogs. Surger), 64:214-225, 1968. 
24. Warren W.D., Zeppa R.. Fomon J.J.: Selective transsplenic decompression of 
gastroesophageal varices by distal splenorenal shunt. Ann. Surg. 166:437-
455. 1967. 
25. Warren w.n .. Rudman D., Millikan W .. et al.: The metabolic basis of porta-
systemic encephalopathy and the effect of selective vs. nonselective shunts. 
Ann. Surg. 180:573-579. 1974. 
26. Warren W.D. Millikan W.J. Jr., Henderson J.M .. et al.: Ten years portal 
hypertensive surgery at Emory: Results and new perspectives. A'ln. Surg. 
195:530-542. 1982. 
SELF-ASSESSMENT ANSWERS 
1. d 
2. False 
3. d 
4. c 
5. a, b, c & d 
752 
6. False 
7. True 
8. False 
9. False 
10. False 
NOTES 
753 
